Exact Mass: 776.5398

Rutamycin

C44H72O11 (776.5074)

An oligomycin with formula C44H72O11 that is oligomycin A in which the methyl substituent adjacent to the spirocyclic centre has been replaced by a hydrogen. D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D009840 - Oligomycins C784 - Protein Synthesis Inhibitor > C261 - Macrolide Antibiotic D000890 - Anti-Infective Agents > D000935 - Antifungal Agents D004791 - Enzyme Inhibitors > D014475 - Uncoupling Agents C254 - Anti-Infective Agent > C258 - Antibiotic Same as: D05778

Gamithromycin

C40H76N2O12 (776.5398)

D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents C784 - Protein Synthesis Inhibitor > C261 - Macrolide Antibiotic C254 - Anti-Infective Agent > C258 - Antibiotic

PG(18:0/18:1(9Z))

C42H81O10P (776.5567)

PG(18:0/18:1(9Z)) is a phosphatidylglycerol or glycerophospholipid (PG or GP). It is a glycerophospholipid in which a phosphoglycerol moiety occupies a glycerol substitution site. As is the case with diacylglycerols, phosphatidylglycerols can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PG(18:0/18:1(9Z)), in particular, consists of one chain of stearic acid at the C-1 position and one chain of oleic acid at the C-2 position. The stearic acid moiety is derived from animal fats, coco butter and sesame oil, while the oleic acid moiety is derived from vegetable oils, especially olive and canola oil. Phosphatidylglycerol is present at a level of 1-2\\% in most animal tissues, but it can be the second most abundant phospholipid in lung surfactant at up to 11\\% of the total. It is well established that the concentration of phosphatidylglycerol increases during fetal development. Phosphatidylglycerol may be present in animal tissues merely as a precursor for diphosphatidylglycerol (cardiolipin). Phosphatidylglycerol is formed from phosphatidic acid by a sequence of enzymatic reactions that proceeds via the intermediate, cytidine diphosphate diacylglycerol (CDP-diacylglycerol). Bioynthesis proceeds by condensation of phosphatidic acid and cytidine triphosphate with elimination of pyrophosphate via the action of phosphatidate cytidyltransferase (or CDP-synthase). CDP-diacylglycerol then reacts with glycerol-3-phosphate via phosphatidylglycerophosphate synthase to form 3-sn-phosphatidyl-1-sn-glycerol 3-phosphoric acid, with the release of cytidine monophosphate (CMP). Finally, phosphatidylglycerol is formed by the action of specific phosphatases. While most phospholipids have a saturated fatty acid on C-1 and an unsaturated fatty acid on C-2 of the glycerol backbone, the fatty acid distribution at the C-1 and C-2 positions of glycerol within phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. PGs have a net charge of -1 at physiological pH and are found in high concentration in mitochondrial membranes and as components of pulmonary surfactant. PG also serves as a precursor for the synthesis of cardiolipin. PG is synthesized from CDP-diacylglycerol and glycerol-3-phosphate. PG(18:0/18:1(9Z)) is a phosphatidylglycerol. Phosphatidylglycerols consist of a glycerol 3-phosphate backbone esterified to either saturated or unsaturated fatty acids on carbons 1 and 2. As is the case with diacylglycerols, phosphatidylglycerols can have many different combinations of fatty acids of varying lengths and saturation attached to the C-1 and C-2 positions. PG(18:0/18:1(9Z)), in particular, consists of one octadecanoyl chain to the C-1 atom, and one 9Z-octadecenoyl to the C-2 atom. In E. coli glycerophospholipid metabolism, phosphatidylglycerol is formed from phosphatidic acid (1,2-diacyl-sn-glycerol 3-phosphate) by a sequence of enzymatic reactions that proceeds via two intermediates, cytidine diphosphate diacylglycerol (CDP-diacylglycerol) and phosphatidylglycerophosphate (PGP, a phosphorylated phosphatidylglycerol). Phosphatidylglycerols, along with CDP-diacylglycerol, also serve as precursor molecules for the synthesis of cardiolipin, a phospholipid found in membranes.

PG(18:0/18:1(11Z))

C42H81O10P (776.5567)

PG(18:0/18:1(11Z)) is a phosphatidylglycerol or glycerophospholipid (PG or GP). It is a glycerophospholipid in which a phosphoglycerol moiety occupies a glycerol substitution site. As is the case with diacylglycerols, phosphatidylglycerols can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PG(18:0/18:1(11Z)), in particular, consists of one chain of stearic acid at the C-1 position and one chain of vaccenic acid at the C-2 position. The stearic acid moiety is derived from animal fats, coco butter and sesame oil, while the vaccenic acid moiety is derived from butter fat and animal fat. Phosphatidylglycerol is present at a level of 1-2\\% in most animal tissues, but it can be the second most abundant phospholipid in lung surfactant at up to 11\\% of the total. It is well established that the concentration of phosphatidylglycerol increases during fetal development. Phosphatidylglycerol may be present in animal tissues merely as a precursor for diphosphatidylglycerol (cardiolipin). Phosphatidylglycerol is formed from phosphatidic acid by a sequence of enzymatic reactions that proceeds via the intermediate, cytidine diphosphate diacylglycerol (CDP-diacylglycerol). Bioynthesis proceeds by condensation of phosphatidic acid and cytidine triphosphate with elimination of pyrophosphate via the action of phosphatidate cytidyltransferase (or CDP-synthase). CDP-diacylglycerol then reacts with glycerol-3-phosphate via phosphatidylglycerophosphate synthase to form 3-sn-phosphatidyl-1-sn-glycerol 3-phosphoric acid, with the release of cytidine monophosphate (CMP). Finally, phosphatidylglycerol is formed by the action of specific phosphatases. While most phospholipids have a saturated fatty acid on C-1 and an unsaturated fatty acid on C-2 of the glycerol backbone, the fatty acid distribution at the C-1 and C-2 positions of glycerol within phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. PGs have a net charge of -1 at physiological pH and are found in high concentration in mitochondrial membranes and as components of pulmonary surfactant. PG also serves as a precursor for the synthesis of cardiolipin. PG is synthesized from CDP-diacylglycerol and glycerol-3-phosphate. PG(18:0/18:1(11Z)) is a phosphatidylglycerol or glycerophospholipid (PG or GP). It is a glycerophospholipid in which a phosphoglycerol moiety occupies a glycerol substitution site. As is the case with diacylglycerols, phosphatidylglycerols can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PG(18:0/18:1(11Z)), in particular, consists of one chain of stearic acid at the C-1 position and one chain of vaccenic acid at the C-2 position. The stearic acid moiety is derived from animal fats, coco butter and sesame oil, while the vaccenic acid moiety is derived from butter fat and animal fat. Phosphatidylglycerol is present at a level of 1-2\\% in most animal tissues, but it can be the second most abundant phospholipid in lung surfactant at up to 11\\% of the total. It is well established that the concentration of phosphatidylglycerol increases during fetal development. Phosphatidylglycerol may be present in animal tissues merely as a precursor for diphosphatidylglycerol (cardiolipin). Phosphatidylglycerol is formed from phosphatidic acid by a sequence of enzymatic reactions that proceeds via the intermediate, cytidine diphosphate diacylglycerol (CDP-diacylglycerol). Bioynthesis proceeds by condensation of phosphatidic acid and cytidine triphosphate with elimination of pyrophosphate via the action of phosphatidate cytidyltransferase (or CDP-synthase). CDP-diacylglycerol then reacts with glycerol-3-phosphate via phosphatidylglycerophosphate synthase to form 3-sn-phosphatidyl-1-sn-glycerol 3-phosphoric acid, with the release of cytidine monophosphate (CMP). Finally, phosphatidylglycerol is formed by the action of specific phosphatases.

PG(18:1(11Z)/18:0)

C42H81O10P (776.5567)

PG(18:1(11Z)/18:0) is a phosphatidylglycerol or glycerophospholipid (PG or GP). It is a glycerophospholipid in which a phosphoglycerol moiety occupies a glycerol substitution site. As is the case with diacylglycerols, phosphatidylglycerols can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PG(18:1(11Z)/18:0), in particular, consists of one chain of vaccenic acid at the C-1 position and one chain of stearic acid at the C-2 position. The vaccenic acid moiety is derived from butter fat and animal fat, while the stearic acid moiety is derived from animal fats, coco butter and sesame oil. Phosphatidylglycerol is present at a level of 1-2\\% in most animal tissues, but it can be the second most abundant phospholipid in lung surfactant at up to 11\\% of the total. It is well established that the concentration of phosphatidylglycerol increases during fetal development. Phosphatidylglycerol may be present in animal tissues merely as a precursor for diphosphatidylglycerol (cardiolipin). Phosphatidylglycerol is formed from phosphatidic acid by a sequence of enzymatic reactions that proceeds via the intermediate, cytidine diphosphate diacylglycerol (CDP-diacylglycerol). Bioynthesis proceeds by condensation of phosphatidic acid and cytidine triphosphate with elimination of pyrophosphate via the action of phosphatidate cytidyltransferase (or CDP-synthase). CDP-diacylglycerol then reacts with glycerol-3-phosphate via phosphatidylglycerophosphate synthase to form 3-sn-phosphatidyl-1-sn-glycerol 3-phosphoric acid, with the release of cytidine monophosphate (CMP). Finally, phosphatidylglycerol is formed by the action of specific phosphatases. While most phospholipids have a saturated fatty acid on C-1 and an unsaturated fatty acid on C-2 of the glycerol backbone, the fatty acid distribution at the C-1 and C-2 positions of glycerol within phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. PGs have a net charge of -1 at physiological pH and are found in high concentration in mitochondrial membranes and as components of pulmonary surfactant. PG also serves as a precursor for the synthesis of cardiolipin. PG is synthesized from CDP-diacylglycerol and glycerol-3-phosphate. PG(18:1(11Z)/18:0) is a phosphatidylglycerol or glycerophospholipid (PG or GP). It is a glycerophospholipid in which a phosphoglycerol moiety occupies a glycerol substitution site. As is the case with diacylglycerols, phosphatidylglycerols can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PG(18:1(11Z)/18:0), in particular, consists of one chain of vaccenic acid at the C-1 position and one chain of stearic acid at the C-2 position. The vaccenic acid moiety is derived from butter fat and animal fat, while the stearic acid moiety is derived from animal fats, coco butter and sesame oil. Phosphatidylglycerol is present at a level of 1-2\\% in most animal tissues, but it can be the second most abundant phospholipid in lung surfactant at up to 11\\% of the total. It is well established that the concentration of phosphatidylglycerol increases during fetal development. Phosphatidylglycerol may be present in animal tissues merely as a precursor for diphosphatidylglycerol (cardiolipin). Phosphatidylglycerol is formed from phosphatidic acid by a sequence of enzymatic reactions that proceeds via the intermediate, cytidine diphosphate diacylglycerol (CDP-diacylglycerol). Bioynthesis proceeds by condensation of phosphatidic acid and cytidine triphosphate with elimination of pyrophosphate via the action of phosphatidate cytidyltransferase (or CDP-synthase). CDP-diacylglycerol then reacts with glycerol-3-phosphate via phosphatidylglycerophosphate synthase to form 3-sn-phosphatidyl-1-sn-glycerol 3-phosphoric acid, with the release of cytidine monophosphate (CMP). Finally, phosphatidylglycerol is formed by the action of specific phosphatases.

PG(18:1(9Z)/18:0)

C42H81O10P (776.5567)

PG(18:1(9Z)/18:0) is a phosphatidylglycerol or glycerophospholipid (PG or GP). It is a glycerophospholipid in which a phosphoglycerol moiety occupies a glycerol substitution site. As is the case with diacylglycerols, phosphatidylglycerols can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PG(18:1(9Z)/18:0), in particular, consists of one chain of oleic acid at the C-1 position and one chain of stearic acid at the C-2 position. The oleic acid moiety is derived from vegetable oils, especially olive and canola oil, while the stearic acid moiety is derived from animal fats, coco butter and sesame oil. Phosphatidylglycerol is present at a level of 1-2\\% in most animal tissues, but it can be the second most abundant phospholipid in lung surfactant at up to 11\\% of the total. It is well established that the concentration of phosphatidylglycerol increases during fetal development. Phosphatidylglycerol may be present in animal tissues merely as a precursor for diphosphatidylglycerol (cardiolipin). Phosphatidylglycerol is formed from phosphatidic acid by a sequence of enzymatic reactions that proceeds via the intermediate, cytidine diphosphate diacylglycerol (CDP-diacylglycerol). Bioynthesis proceeds by condensation of phosphatidic acid and cytidine triphosphate with elimination of pyrophosphate via the action of phosphatidate cytidyltransferase (or CDP-synthase). CDP-diacylglycerol then reacts with glycerol-3-phosphate via phosphatidylglycerophosphate synthase to form 3-sn-phosphatidyl-1-sn-glycerol 3-phosphoric acid, with the release of cytidine monophosphate (CMP). Finally, phosphatidylglycerol is formed by the action of specific phosphatases. While most phospholipids have a saturated fatty acid on C-1 and an unsaturated fatty acid on C-2 of the glycerol backbone, the fatty acid distribution at the C-1 and C-2 positions of glycerol within phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. PGs have a net charge of -1 at physiological pH and are found in high concentration in mitochondrial membranes and as components of pulmonary surfactant. PG also serves as a precursor for the synthesis of cardiolipin. PG is synthesized from CDP-diacylglycerol and glycerol-3-phosphate. PG(18:1(9Z)/18:0) is a phosphatidylglycerol. Phosphatidylglycerols consist of a glycerol 3-phosphate backbone esterified to either saturated or unsaturated fatty acids on carbons 1 and 2. As is the case with diacylglycerols, phosphatidylglycerols can have many different combinations of fatty acids of varying lengths and saturation attached to the C-1 and C-2 positions. PG(18:1(9Z)/18:0), in particular, consists of one 9Z-octadecenoyl chain to the C-1 atom, and one octadecanoyl to the C-2 atom. In E. coli glycerophospholipid metabolism, phosphatidylglycerol is formed from phosphatidic acid (1,2-diacyl-sn-glycerol 3-phosphate) by a sequence of enzymatic reactions that proceeds via two intermediates, cytidine diphosphate diacylglycerol (CDP-diacylglycerol) and phosphatidylglycerophosphate (PGP, a phosphorylated phosphatidylglycerol). Phosphatidylglycerols, along with CDP-diacylglycerol, also serve as precursor molecules for the synthesis of cardiolipin, a phospholipid found in membranes.

PA(20:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z))

C45H77O8P (776.5356)

PA(20:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z)) is a phosphatidic acid. It is a glycerophospholipid in which a phosphate moiety occupies a glycerol substitution site. As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PA(20:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z)), in particular, consists of one chain of arachidic acid at the C-1 position and one chain of docosahexaenoic acid at the C-2 position. Phosphatidic acids are quite rare but are extremely important as intermediates in the biosynthesis of triacylglycerols and phospholipids.

PA(20:1(11Z)/22:5(4Z,7Z,10Z,13Z,16Z))

C45H77O8P (776.5356)

PA(20:1(11Z)/22:5(4Z,7Z,10Z,13Z,16Z)) is a phosphatidic acid. It is a glycerophospholipid in which a phosphate moiety occupies a glycerol substitution site. As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PA(20:1(11Z)/22:5(4Z,7Z,10Z,13Z,16Z)), in particular, consists of one chain of eicosenoic acid at the C-1 position and one chain of osbond acid at the C-2 position. Phosphatidic acids are quite rare but are extremely important as intermediates in the biosynthesis of triacylglycerols and phospholipids.

PA(20:1(11Z)/22:5(7Z,10Z,13Z,16Z,19Z))

C45H77O8P (776.5356)

PA(20:1(11Z)/22:5(7Z,10Z,13Z,16Z,19Z)) is a phosphatidic acid. It is a glycerophospholipid in which a phosphate moiety occupies a glycerol substitution site. As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PA(20:1(11Z)/22:5(7Z,10Z,13Z,16Z,19Z)), in particular, consists of one chain of eicosenoic acid at the C-1 position and one chain of clupanodonic acid at the C-2 position. Phosphatidic acids are quite rare but are extremely important as intermediates in the biosynthesis of triacylglycerols and phospholipids.

PA(20:4(5Z,8Z,11Z,14Z)/22:2(13Z,16Z))

C45H77O8P (776.5356)

PA(20:4(5Z,8Z,11Z,14Z)/22:2(13Z,16Z)) is a phosphatidic acid. It is a glycerophospholipid in which a phosphate moiety occupies a glycerol substitution site. As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PA(20:4(5Z,8Z,11Z,14Z)/22:2(13Z,16Z)), in particular, consists of one chain of arachidonic acid at the C-1 position and one chain of docosadienoic acid at the C-2 position. Phosphatidic acids are quite rare but are extremely important as intermediates in the biosynthesis of triacylglycerols and phospholipids.

PA(20:4(8Z,11Z,14Z,17Z)/22:2(13Z,16Z))

C45H77O8P (776.5356)

PA(20:4(8Z,11Z,14Z,17Z)/22:2(13Z,16Z)) is a phosphatidic acid. It is a glycerophospholipid in which a phosphate moiety occupies a glycerol substitution site. As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PA(20:4(8Z,11Z,14Z,17Z)/22:2(13Z,16Z)), in particular, consists of one chain of eicosatetraenoic acid at the C-1 position and one chain of docosadienoic acid at the C-2 position. Phosphatidic acids are quite rare but are extremely important as intermediates in the biosynthesis of triacylglycerols and phospholipids.

PA(20:5(5Z,8Z,11Z,14Z,17Z)/22:1(13Z))

C45H77O8P (776.5356)

PA(20:5(5Z,8Z,11Z,14Z,17Z)/22:1(13Z)) is a phosphatidic acid. It is a glycerophospholipid in which a phosphate moiety occupies a glycerol substitution site. As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PA(20:5(5Z,8Z,11Z,14Z,17Z)/22:1(13Z)), in particular, consists of one chain of eicosapentaenoic acid at the C-1 position and one chain of erucic acid at the C-2 position. Phosphatidic acids are quite rare but are extremely important as intermediates in the biosynthesis of triacylglycerols and phospholipids.

PA(22:1(13Z)/20:5(5Z,8Z,11Z,14Z,17Z))

C45H77O8P (776.5356)

PA(22:1(13Z)/20:5(5Z,8Z,11Z,14Z,17Z)) is a phosphatidic acid. It is a glycerophospholipid in which a phosphate moiety occupies a glycerol substitution site. As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PA(22:1(13Z)/20:5(5Z,8Z,11Z,14Z,17Z)), in particular, consists of one chain of erucic acid at the C-1 position and one chain of eicosapentaenoic acid at the C-2 position. Phosphatidic acids are quite rare but are extremely important as intermediates in the biosynthesis of triacylglycerols and phospholipids.

PA(22:2(13Z,16Z)/20:4(5Z,8Z,11Z,14Z))

C45H77O8P (776.5356)

PA(22:2(13Z,16Z)/20:4(5Z,8Z,11Z,14Z)) is a phosphatidic acid. It is a glycerophospholipid in which a phosphate moiety occupies a glycerol substitution site. As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PA(22:2(13Z,16Z)/20:4(5Z,8Z,11Z,14Z)), in particular, consists of one chain of docosadienoic acid at the C-1 position and one chain of arachidonic acid at the C-2 position. Phosphatidic acids are quite rare but are extremely important as intermediates in the biosynthesis of triacylglycerols and phospholipids.

PA(22:2(13Z,16Z)/20:4(8Z,11Z,14Z,17Z))

C45H77O8P (776.5356)

PA(22:2(13Z,16Z)/20:4(8Z,11Z,14Z,17Z)) is a phosphatidic acid. It is a glycerophospholipid in which a phosphate moiety occupies a glycerol substitution site. As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PA(22:2(13Z,16Z)/20:4(8Z,11Z,14Z,17Z)), in particular, consists of one chain of docosadienoic acid at the C-1 position and one chain of eicosatetraenoic acid at the C-2 position. Phosphatidic acids are quite rare but are extremely important as intermediates in the biosynthesis of triacylglycerols and phospholipids.

PA(22:5(4Z,7Z,10Z,13Z,16Z)/20:1(11Z))

C45H77O8P (776.5356)

PA(22:5(4Z,7Z,10Z,13Z,16Z)/20:1(11Z)) is a phosphatidic acid. It is a glycerophospholipid in which a phosphate moiety occupies a glycerol substitution site. As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PA(22:5(4Z,7Z,10Z,13Z,16Z)/20:1(11Z)), in particular, consists of one chain of osbond acid at the C-1 position and one chain of eicosenoic acid at the C-2 position. Phosphatidic acids are quite rare but are extremely important as intermediates in the biosynthesis of triacylglycerols and phospholipids.

PA(22:5(7Z,10Z,13Z,16Z,19Z)/20:1(11Z))

C45H77O8P (776.5356)

PA(22:5(7Z,10Z,13Z,16Z,19Z)/20:1(11Z)) is a phosphatidic acid. It is a glycerophospholipid in which a phosphate moiety occupies a glycerol substitution site. As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PA(22:5(7Z,10Z,13Z,16Z,19Z)/20:1(11Z)), in particular, consists of one chain of clupanodonic acid at the C-1 position and one chain of eicosenoic acid at the C-2 position. Phosphatidic acids are quite rare but are extremely important as intermediates in the biosynthesis of triacylglycerols and phospholipids.

PA(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/20:0)

C45H77O8P (776.5356)

PA(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/20:0) is a phosphatidic acid. It is a glycerophospholipid in which a phosphate moiety occupies a glycerol substitution site. As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PA(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/20:0), in particular, consists of one chain of docosahexaenoic acid at the C-1 position and one chain of arachidic acid at the C-2 position. Phosphatidic acids are quite rare but are extremely important as intermediates in the biosynthesis of triacylglycerols and phospholipids.

PA(20:2(11Z,14Z)/22:4(7Z,10Z,13Z,16Z))

C45H77O8P (776.5356)

PA(20:2(11Z,14Z)/22:4(7Z,10Z,13Z,16Z)) is a phosphatidic acid. It is a glycerophospholipid in which a phosphate moiety occupies a glycerol substitution site. As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PA(20:2(11Z,14Z)/22:4(7Z,10Z,13Z,16Z)), in particular, consists of one chain of eicosadienoic acid at the C-1 position and one chain of adrenic acid at the C-2 position. Phosphatidic acids are quite rare but are extremely important as intermediates in the biosynthesis of triacylglycerols and phospholipids.

PA(22:4(7Z,10Z,13Z,16Z)/20:2(11Z,14Z))

C45H77O8P (776.5356)

PA(22:4(7Z,10Z,13Z,16Z)/20:2(11Z,14Z)) is a phosphatidic acid. It is a glycerophospholipid in which a phosphate moiety occupies a glycerol substitution site. As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PA(22:4(7Z,10Z,13Z,16Z)/20:2(11Z,14Z)), in particular, consists of one chain of adrenic acid at the C-1 position and one chain of eicosadienoic acid at the C-2 position. Phosphatidic acids are quite rare but are extremely important as intermediates in the biosynthesis of triacylglycerols and phospholipids.

(1R,4E,5'R,6R,6'R,7S,8S,10S,11S,12R,14S,15R,16S,18E,20E,22S,25R,27S,29S)-22-Ethyl-7,11,14,15-tetrahydroxy-6'-(2-hydroxypropyl)-5',6,8,10,12,14,16,29-octamethylspiro[2,26-dioxabicyclo[23.3.1]nonacosa-4,18,20-triene-27,2'-oxane]-3,9,13-trione

C44H72O11 (776.5074)

Gamithromycin

C40H76N2O12 (776.5398)

Tecoflex

C43H76N4O8 (776.5663)

PA(18:0/PGF1alpha)

C41H77O11P (776.5203)

PA(18:0/PGF1alpha) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(18:0/PGF1alpha), in particular, consists of one chain of one octadecanoyl at the C-1 position and one chain of Prostaglandin F1alpha at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

PA(PGF1alpha/18:0)

C41H77O11P (776.5203)

PA(PGF1alpha/18:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(PGF1alpha/18:0), in particular, consists of one chain of one Prostaglandin F1alpha at the C-1 position and one chain of octadecanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

PA(21:0/18:1(12Z)-2OH(9,10))

C42H81O10P (776.5567)

PA(21:0/18:1(12Z)-2OH(9,10)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(21:0/18:1(12Z)-2OH(9,10)), in particular, consists of one chain of one heneicosanoyl at the C-1 position and one chain of 9,10-hydroxy-octadecenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

PA(18:1(12Z)-2OH(9,10)/21:0)

C42H81O10P (776.5567)

PA(18:1(12Z)-2OH(9,10)/21:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(18:1(12Z)-2OH(9,10)/21:0), in particular, consists of one chain of one 9,10-hydroxy-octadecenoyl at the C-1 position and one chain of heneicosanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

PA(a-21:0/18:1(12Z)-2OH(9,10))

C42H81O10P (776.5567)

PA(a-21:0/18:1(12Z)-2OH(9,10)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(a-21:0/18:1(12Z)-2OH(9,10)), in particular, consists of one chain of one 18-methyleicosanoyl at the C-1 position and one chain of 9,10-hydroxy-octadecenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

PA(18:1(12Z)-2OH(9,10)/a-21:0)

C42H81O10P (776.5567)

PA(18:1(12Z)-2OH(9,10)/a-21:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(18:1(12Z)-2OH(9,10)/a-21:0), in particular, consists of one chain of one 9,10-hydroxy-octadecenoyl at the C-1 position and one chain of 18-methyleicosanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

PA(i-18:0/PGF1alpha)

C41H77O11P (776.5203)

PA(i-18:0/PGF1alpha) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(i-18:0/PGF1alpha), in particular, consists of one chain of one 16-methylheptadecanoyl at the C-1 position and one chain of Prostaglandin F1alpha at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

PA(PGF1alpha/i-18:0)

C41H77O11P (776.5203)

PA(PGF1alpha/i-18:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(PGF1alpha/i-18:0), in particular, consists of one chain of one Prostaglandin F1alpha at the C-1 position and one chain of 16-methylheptadecanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

PA(i-21:0/18:1(12Z)-2OH(9,10))

C42H81O10P (776.5567)

PA(i-21:0/18:1(12Z)-2OH(9,10)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(i-21:0/18:1(12Z)-2OH(9,10)), in particular, consists of one chain of one 19-methyleicosanoyl at the C-1 position and one chain of 9,10-hydroxy-octadecenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

PA(18:1(12Z)-2OH(9,10)/i-21:0)

C42H81O10P (776.5567)

PA(18:1(12Z)-2OH(9,10)/i-21:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(18:1(12Z)-2OH(9,10)/i-21:0), in particular, consists of one chain of one 9,10-hydroxy-octadecenoyl at the C-1 position and one chain of 19-methyleicosanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

PG(a-17:0/18:1(12Z)-O(9S,10R))

C41H77O11P (776.5203)

PG(a-17:0/18:1(12Z)-O(9S,10R)) is an oxidized phosphatidylglycerol (PG). Oxidized phosphatidylglycerols are glycerophospholipids in which a phosphoglycerol moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidylglycerols belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidylglycerols can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PG(a-17:0/18:1(12Z)-O(9S,10R)), in particular, consists of one chain of one 14-methylhexadecanoyl at the C-1 position and one chain of 9,10-epoxy-octadecenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PGs can be synthesized via three different routes. In one route, the oxidized PG is synthetized de novo following the same mechanisms as for PGs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PG backbone, mainly through the action of LOX (PMID: 33329396).

PG(18:1(12Z)-O(9S,10R)/a-17:0)

C41H77O11P (776.5203)

PG(18:1(12Z)-O(9S,10R)/a-17:0) is an oxidized phosphatidylglycerol (PG). Oxidized phosphatidylglycerols are glycerophospholipids in which a phosphoglycerol moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidylglycerols belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidylglycerols can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PG(18:1(12Z)-O(9S,10R)/a-17:0), in particular, consists of one chain of one 9,10-epoxy-octadecenoyl at the C-1 position and one chain of 14-methylhexadecanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PGs can be synthesized via three different routes. In one route, the oxidized PG is synthetized de novo following the same mechanisms as for PGs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PG backbone, mainly through the action of LOX (PMID: 33329396).

PG(a-17:0/18:1(9Z)-O(12,13))

C41H77O11P (776.5203)

PG(a-17:0/18:1(9Z)-O(12,13)) is an oxidized phosphatidylglycerol (PG). Oxidized phosphatidylglycerols are glycerophospholipids in which a phosphoglycerol moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidylglycerols belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidylglycerols can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PG(a-17:0/18:1(9Z)-O(12,13)), in particular, consists of one chain of one 14-methylhexadecanoyl at the C-1 position and one chain of 12,13-epoxy-octadecenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PGs can be synthesized via three different routes. In one route, the oxidized PG is synthetized de novo following the same mechanisms as for PGs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PG backbone, mainly through the action of LOX (PMID: 33329396).

PG(18:1(9Z)-O(12,13)/a-17:0)

C41H77O11P (776.5203)

PG(18:1(9Z)-O(12,13)/a-17:0) is an oxidized phosphatidylglycerol (PG). Oxidized phosphatidylglycerols are glycerophospholipids in which a phosphoglycerol moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidylglycerols belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidylglycerols can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PG(18:1(9Z)-O(12,13)/a-17:0), in particular, consists of one chain of one 12,13-epoxy-octadecenoyl at the C-1 position and one chain of 14-methylhexadecanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PGs can be synthesized via three different routes. In one route, the oxidized PG is synthetized de novo following the same mechanisms as for PGs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PG backbone, mainly through the action of LOX (PMID: 33329396).

PG(i-17:0/18:1(12Z)-O(9S,10R))

C41H77O11P (776.5203)

PG(i-17:0/18:1(12Z)-O(9S,10R)) is an oxidized phosphatidylglycerol (PG). Oxidized phosphatidylglycerols are glycerophospholipids in which a phosphoglycerol moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidylglycerols belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidylglycerols can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PG(i-17:0/18:1(12Z)-O(9S,10R)), in particular, consists of one chain of one 15-methylhexadecanoyl at the C-1 position and one chain of 9,10-epoxy-octadecenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PGs can be synthesized via three different routes. In one route, the oxidized PG is synthetized de novo following the same mechanisms as for PGs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PG backbone, mainly through the action of LOX (PMID: 33329396).

PG(18:1(12Z)-O(9S,10R)/i-17:0)

C41H77O11P (776.5203)

PG(18:1(12Z)-O(9S,10R)/i-17:0) is an oxidized phosphatidylglycerol (PG). Oxidized phosphatidylglycerols are glycerophospholipids in which a phosphoglycerol moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidylglycerols belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidylglycerols can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PG(18:1(12Z)-O(9S,10R)/i-17:0), in particular, consists of one chain of one 9,10-epoxy-octadecenoyl at the C-1 position and one chain of 15-methylhexadecanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PGs can be synthesized via three different routes. In one route, the oxidized PG is synthetized de novo following the same mechanisms as for PGs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PG backbone, mainly through the action of LOX (PMID: 33329396).

PG(i-17:0/18:1(9Z)-O(12,13))

C41H77O11P (776.5203)

PG(i-17:0/18:1(9Z)-O(12,13)) is an oxidized phosphatidylglycerol (PG). Oxidized phosphatidylglycerols are glycerophospholipids in which a phosphoglycerol moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidylglycerols belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidylglycerols can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PG(i-17:0/18:1(9Z)-O(12,13)), in particular, consists of one chain of one 15-methylhexadecanoyl at the C-1 position and one chain of 12,13-epoxy-octadecenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PGs can be synthesized via three different routes. In one route, the oxidized PG is synthetized de novo following the same mechanisms as for PGs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PG backbone, mainly through the action of LOX (PMID: 33329396).

PG(18:1(9Z)-O(12,13)/i-17:0)

C41H77O11P (776.5203)

PG(18:1(9Z)-O(12,13)/i-17:0) is an oxidized phosphatidylglycerol (PG). Oxidized phosphatidylglycerols are glycerophospholipids in which a phosphoglycerol moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidylglycerols belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidylglycerols can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PG(18:1(9Z)-O(12,13)/i-17:0), in particular, consists of one chain of one 12,13-epoxy-octadecenoyl at the C-1 position and one chain of 15-methylhexadecanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PGs can be synthesized via three different routes. In one route, the oxidized PG is synthetized de novo following the same mechanisms as for PGs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PG backbone, mainly through the action of LOX (PMID: 33329396).

SM(d16:2(4E,8Z)/22:6(5Z,8E,10Z,13Z,15E,19Z)-2OH(7S, 17S))

C43H73N2O8P (776.5104)

SM(d16:2(4E,8Z)/22:6(5Z,8E,10Z,13Z,15E,19Z)-2OH(7S, 17S)) is a type of oxidized sphingolipid found in animal cell membranes. It usually consists of phosphorylcholine and ceramide. SM(d16:2(4E,8Z)/22:6(5Z,8E,10Z,13Z,15E,19Z)-2OH(7S, 17S)) consists of a sphingosine backbone and a Resolvin D5 chain. In humans, sphingomyelin is the only membrane phospholipid not derived from glycerol. Like all sphingolipids, SM has a ceramide core (sphingosine bonded to a fatty acid via an amide linkage). In addition, it contains one polar head group, which is either phosphocholine or phosphoethanolamine. The plasma membrane of cells is highly enriched in sphingomyelin and is considered largely to be found in the exoplasmic leaflet of the cell membrane. However, there is some evidence that there may also be a sphingomyelin pool in the inner leaflet of the membrane. Moreover, neutral sphingomyelinase-2, an enzyme that breaks down sphingomyelin into ceramide, has been found to localize exclusively to the inner leaflet further suggesting that there may be sphingomyelin present there. Sphingomyelin can accumulate in a rare hereditary disease called Niemann-Pick Disease, types A and B. Niemann-Pick disease is a genetically-inherited disease caused by a deficiency in the enzyme sphingomyelinase, which causes the accumulation of sphingomyelin in spleen, liver, lungs, bone marrow, and the brain, causing irreversible neurological damage. SMs play a role in signal transduction. Sphingomyelins are synthesized by the transfer of phosphorylcholine from phosphatidylcholine to a ceramide in a reaction catalyzed by sphingomyelin synthase.

SM(d16:2(4E,8Z)/22:6(4Z,7Z,11E,13Z,15E,19Z)-2OH(10S,17))

C43H73N2O8P (776.5104)

SM(d16:2(4E,8Z)/22:6(4Z,7Z,11E,13Z,15E,19Z)-2OH(10S,17)) is a type of oxidized sphingolipid found in animal cell membranes. It usually consists of phosphorylcholine and ceramide. SM(d16:2(4E,8Z)/22:6(4Z,7Z,11E,13Z,15E,19Z)-2OH(10S,17)) consists of a sphingosine backbone and a Protectin DX chain. In humans, sphingomyelin is the only membrane phospholipid not derived from glycerol. Like all sphingolipids, SM has a ceramide core (sphingosine bonded to a fatty acid via an amide linkage). In addition, it contains one polar head group, which is either phosphocholine or phosphoethanolamine. The plasma membrane of cells is highly enriched in sphingomyelin and is considered largely to be found in the exoplasmic leaflet of the cell membrane. However, there is some evidence that there may also be a sphingomyelin pool in the inner leaflet of the membrane. Moreover, neutral sphingomyelinase-2, an enzyme that breaks down sphingomyelin into ceramide, has been found to localize exclusively to the inner leaflet further suggesting that there may be sphingomyelin present there. Sphingomyelin can accumulate in a rare hereditary disease called Niemann-Pick Disease, types A and B. Niemann-Pick disease is a genetically-inherited disease caused by a deficiency in the enzyme sphingomyelinase, which causes the accumulation of sphingomyelin in spleen, liver, lungs, bone marrow, and the brain, causing irreversible neurological damage. SMs play a role in signal transduction. Sphingomyelins are synthesized by the transfer of phosphorylcholine from phosphatidylcholine to a ceramide in a reaction catalyzed by sphingomyelin synthase.

SM(d17:1/22:6(5Z,7Z,10Z,13Z,16Z,19Z)-OH(4))

C44H77N2O7P (776.5468)

SM(d17:1/22:6(5Z,7Z,10Z,13Z,16Z,19Z)-OH(4)) is a type of oxidized sphingolipid found in animal cell membranes. It usually consists of phosphorylcholine and ceramide. SM(d17:1/22:6(5Z,7Z,10Z,13Z,16Z,19Z)-OH(4)) consists of a sphingosine backbone and a 4-hydroxy-docosahexaenoyl chain. In humans, sphingomyelin is the only membrane phospholipid not derived from glycerol. Like all sphingolipids, SM has a ceramide core (sphingosine bonded to a fatty acid via an amide linkage). In addition, it contains one polar head group, which is either phosphocholine or phosphoethanolamine. The plasma membrane of cells is highly enriched in sphingomyelin and is considered largely to be found in the exoplasmic leaflet of the cell membrane. However, there is some evidence that there may also be a sphingomyelin pool in the inner leaflet of the membrane. Moreover, neutral sphingomyelinase-2, an enzyme that breaks down sphingomyelin into ceramide, has been found to localize exclusively to the inner leaflet further suggesting that there may be sphingomyelin present there. Sphingomyelin can accumulate in a rare hereditary disease called Niemann-Pick Disease, types A and B. Niemann-Pick disease is a genetically-inherited disease caused by a deficiency in the enzyme sphingomyelinase, which causes the accumulation of sphingomyelin in spleen, liver, lungs, bone marrow, and the brain, causing irreversible neurological damage. SMs play a role in signal transduction. Sphingomyelins are synthesized by the transfer of phosphorylcholine from phosphatidylcholine to a ceramide in a reaction catalyzed by sphingomyelin synthase.

SM(d17:1/22:6(4Z,8Z,10Z,13Z,16Z,19Z)-OH(7))

C44H77N2O7P (776.5468)

SM(d17:1/22:6(4Z,8Z,10Z,13Z,16Z,19Z)-OH(7)) is a type of oxidized sphingolipid found in animal cell membranes. It usually consists of phosphorylcholine and ceramide. SM(d17:1/22:6(4Z,8Z,10Z,13Z,16Z,19Z)-OH(7)) consists of a sphingosine backbone and a 7-hydroxy-docosahexaenoyl chain. In humans, sphingomyelin is the only membrane phospholipid not derived from glycerol. Like all sphingolipids, SM has a ceramide core (sphingosine bonded to a fatty acid via an amide linkage). In addition, it contains one polar head group, which is either phosphocholine or phosphoethanolamine. The plasma membrane of cells is highly enriched in sphingomyelin and is considered largely to be found in the exoplasmic leaflet of the cell membrane. However, there is some evidence that there may also be a sphingomyelin pool in the inner leaflet of the membrane. Moreover, neutral sphingomyelinase-2, an enzyme that breaks down sphingomyelin into ceramide, has been found to localize exclusively to the inner leaflet further suggesting that there may be sphingomyelin present there. Sphingomyelin can accumulate in a rare hereditary disease called Niemann-Pick Disease, types A and B. Niemann-Pick disease is a genetically-inherited disease caused by a deficiency in the enzyme sphingomyelinase, which causes the accumulation of sphingomyelin in spleen, liver, lungs, bone marrow, and the brain, causing irreversible neurological damage. SMs play a role in signal transduction. Sphingomyelins are synthesized by the transfer of phosphorylcholine from phosphatidylcholine to a ceramide in a reaction catalyzed by sphingomyelin synthase.

SM(d17:1/22:6(4Z,7Z,10Z,12E,16Z,19Z)-OH(14))

C44H77N2O7P (776.5468)

SM(d17:1/22:6(4Z,7Z,10Z,12E,16Z,19Z)-OH(14)) is a type of oxidized sphingolipid found in animal cell membranes. It usually consists of phosphorylcholine and ceramide. SM(d17:1/22:6(4Z,7Z,10Z,12E,16Z,19Z)-OH(14)) consists of a sphingosine backbone and a 14-hydroxy-docosahexaenoyl chain. In humans, sphingomyelin is the only membrane phospholipid not derived from glycerol. Like all sphingolipids, SM has a ceramide core (sphingosine bonded to a fatty acid via an amide linkage). In addition, it contains one polar head group, which is either phosphocholine or phosphoethanolamine. The plasma membrane of cells is highly enriched in sphingomyelin and is considered largely to be found in the exoplasmic leaflet of the cell membrane. However, there is some evidence that there may also be a sphingomyelin pool in the inner leaflet of the membrane. Moreover, neutral sphingomyelinase-2, an enzyme that breaks down sphingomyelin into ceramide, has been found to localize exclusively to the inner leaflet further suggesting that there may be sphingomyelin present there. Sphingomyelin can accumulate in a rare hereditary disease called Niemann-Pick Disease, types A and B. Niemann-Pick disease is a genetically-inherited disease caused by a deficiency in the enzyme sphingomyelinase, which causes the accumulation of sphingomyelin in spleen, liver, lungs, bone marrow, and the brain, causing irreversible neurological damage. SMs play a role in signal transduction. Sphingomyelins are synthesized by the transfer of phosphorylcholine from phosphatidylcholine to a ceramide in a reaction catalyzed by sphingomyelin synthase.

SM(d17:1/22:6(4Z,7Z,10Z,13E,15E,19Z)-OH(17))

C44H77N2O7P (776.5468)

SM(d17:1/22:6(4Z,7Z,10Z,13E,15E,19Z)-OH(17)) is a type of oxidized sphingolipid found in animal cell membranes. It usually consists of phosphorylcholine and ceramide. SM(d17:1/22:6(4Z,7Z,10Z,13E,15E,19Z)-OH(17)) consists of a sphingosine backbone and a 17-hydroxy-docosahexaenoyl chain. In humans, sphingomyelin is the only membrane phospholipid not derived from glycerol. Like all sphingolipids, SM has a ceramide core (sphingosine bonded to a fatty acid via an amide linkage). In addition, it contains one polar head group, which is either phosphocholine or phosphoethanolamine. The plasma membrane of cells is highly enriched in sphingomyelin and is considered largely to be found in the exoplasmic leaflet of the cell membrane. However, there is some evidence that there may also be a sphingomyelin pool in the inner leaflet of the membrane. Moreover, neutral sphingomyelinase-2, an enzyme that breaks down sphingomyelin into ceramide, has been found to localize exclusively to the inner leaflet further suggesting that there may be sphingomyelin present there. Sphingomyelin can accumulate in a rare hereditary disease called Niemann-Pick Disease, types A and B. Niemann-Pick disease is a genetically-inherited disease caused by a deficiency in the enzyme sphingomyelinase, which causes the accumulation of sphingomyelin in spleen, liver, lungs, bone marrow, and the brain, causing irreversible neurological damage. SMs play a role in signal transduction. Sphingomyelins are synthesized by the transfer of phosphorylcholine from phosphatidylcholine to a ceramide in a reaction catalyzed by sphingomyelin synthase.

SM(d17:1/22:5(4Z,7Z,10Z,13Z,19Z)-O(16,17))

C44H77N2O7P (776.5468)

SM(d17:1/22:5(4Z,7Z,10Z,13Z,19Z)-O(16,17)) is a type of oxidized sphingolipid found in animal cell membranes. It usually consists of phosphorylcholine and ceramide. SM(d17:1/22:5(4Z,7Z,10Z,13Z,19Z)-O(16,17)) consists of a sphingosine backbone and a 16,17-epoxy-docosapentaenoyl chain. In humans, sphingomyelin is the only membrane phospholipid not derived from glycerol. Like all sphingolipids, SM has a ceramide core (sphingosine bonded to a fatty acid via an amide linkage). In addition, it contains one polar head group, which is either phosphocholine or phosphoethanolamine. The plasma membrane of cells is highly enriched in sphingomyelin and is considered largely to be found in the exoplasmic leaflet of the cell membrane. However, there is some evidence that there may also be a sphingomyelin pool in the inner leaflet of the membrane. Moreover, neutral sphingomyelinase-2, an enzyme that breaks down sphingomyelin into ceramide, has been found to localize exclusively to the inner leaflet further suggesting that there may be sphingomyelin present there. Sphingomyelin can accumulate in a rare hereditary disease called Niemann-Pick Disease, types A and B. Niemann-Pick disease is a genetically-inherited disease caused by a deficiency in the enzyme sphingomyelinase, which causes the accumulation of sphingomyelin in spleen, liver, lungs, bone marrow, and the brain, causing irreversible neurological damage. SMs play a role in signal transduction. Sphingomyelins are synthesized by the transfer of phosphorylcholine from phosphatidylcholine to a ceramide in a reaction catalyzed by sphingomyelin synthase.

LS-15431

C40H76N2O12 (776.5398)

1-18:3-2-18:2-monogalactosyldiacylglycerol

C45H76O10 (776.5438)

5-Deooxy,6,7-deepoxy,6,7-didehydro,20-pentadecanoyl-Huratoxin

C49H76O7 (776.5591)

(2S)-1-O-eicosapentaenoyl-2-O-palmitoyl-3-O-beta-D-galactopyranosylglycerol

C45H76O10 (776.5438)

1-18:2-2-18:3-monogalactosyldiacylglycerol

C45H76O10 (776.5438)

[1-[[2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxy-3-[octadec-11-enoyl]oxypropan-2-yl] octadecanoate

C42H81O10P (776.5567)

PG 36:1

C42H81O10P (776.5567)

Found in mouse kidney; TwoDicalId=383; MgfFile=160827_Kidney_EPA_Neg_06; MgfId=1084

[2.3-dihydroxypropoxy][3-[octadec-9-enoyloxy]-2-(octadecanoyloxy)propoxy]phosphinic acid

C42H81O10P (776.5567)

PG(18:0/18:1)[U]

C42H81O10P (776.5567)

PG(18:0/18:1)

C42H81O10P (776.5567)

1-Stearoyl-2-Oleoyl-sn-Glycero-3-[Phospho-rac-(1-glycerol)]

C42H81O10P (776.5567)

CHAULMOSULFONE

C48H76N2O4S (776.5525)

MGDG(18:2(9Z,12Z)/18:3(9Z,12Z,15Z))

C45H76O10 (776.5438)

1-(6-[3]-ladderane-hexanoyl)-2-(8-[3]-ladderane-octanyl)-sn-glycero-3-phospho-(1-sn-glycerol)

C44H73O9P (776.4992)

PG(36:1)

C42H81O10P (776.5567)

PG(14:0/22:1(11Z))

C42H81O10P (776.5567)

PG(14:1(9Z)/22:0)

C42H81O10P (776.5567)

PG(15:1(9Z)/21:0)

C42H81O10P (776.5567)

PG(16:1(9Z)/20:0)

C42H81O10P (776.5567)

PG(17:0/19:1(9Z))

C42H81O10P (776.5567)

PG(17:1(9Z)/19:0)

C42H81O10P (776.5567)

PG(19:0/17:1(9Z))

C42H81O10P (776.5567)

PG(19:1(9Z)/17:0)

C42H81O10P (776.5567)

PG(20:0/16:1(9Z))

C42H81O10P (776.5567)

PG(20:1(11Z)/16:0)

C42H81O10P (776.5567)

PG(21:0/15:1(9Z))

C42H81O10P (776.5567)

PG(22:0/14:1(9Z))

C42H81O10P (776.5567)

PG(22:1(11Z)/14:0)

C42H81O10P (776.5567)

PG(16:0/20:1(11Z))

C42H81O10P (776.5567)

PA(20:2(11Z,14Z)/22:4(7Z,10Z,13Z,16Z))

C45H77O8P (776.5356)

PA(20:4(5Z,8Z,11Z,14Z)/22:2(13Z,16Z))

C45H77O8P (776.5356)

PA(20:5(5Z,8Z,11Z,14Z,17Z)/22:1(11Z))

C45H77O8P (776.5356)

PA(22:1(11Z)/20:5(5Z,8Z,11Z,14Z,17Z))

C45H77O8P (776.5356)

PA(22:2(13Z,16Z)/20:4(5Z,8Z,11Z,14Z))

C45H77O8P (776.5356)

PA(22:4(7Z,10Z,13Z,16Z)/20:2(11Z,14Z))

C45H77O8P (776.5356)

PA(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/20:0)

C45H77O8P (776.5356)

PA(20:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z))

C45H77O8P (776.5356)

MGDG 36:5

C45H76O10 (776.5438)

PG O-38:8

C44H73O9P (776.4992)

PA 42:6

C45H77O8P (776.5356)

Technetium (99mTc) sestamibi

C36H66N6O6Tc (776.5044)

V - Various > V09 - Diagnostic radiopharmaceuticals > V09G - Cardiovascular system > V09GA - Technetium (99mtc) compounds D019995 - Laboratory Chemicals > D007202 - Indicators and Reagents > D019275 - Radiopharmaceuticals C1446 - Radiopharmaceutical Compound > C2124 - Radioconjugate

Tecoflex

C43H76N4O8 (776.5663)

D001697 - Biomedical and Dental Materials

[3-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-2-[(Z)-octadec-9-enoyl]oxypropyl] octadecanoate

C42H81O10P (776.5567)

Oligomycin D

C44H72O11 (776.5074)

D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D009840 - Oligomycins C784 - Protein Synthesis Inhibitor > C261 - Macrolide Antibiotic D000890 - Anti-Infective Agents > D000935 - Antifungal Agents D004791 - Enzyme Inhibitors > D014475 - Uncoupling Agents C254 - Anti-Infective Agent > C258 - Antibiotic

PA(18:0/PGF1alpha)

C41H77O11P (776.5203)

PA(PGF1alpha/18:0)

C41H77O11P (776.5203)

PA(i-18:0/PGF1alpha)

C41H77O11P (776.5203)

PA(PGF1alpha/i-18:0)

C41H77O11P (776.5203)

PG(a-17:0/18:1(12Z)-O(9S,10R))

C41H77O11P (776.5203)

PG(18:1(12Z)-O(9S,10R)/a-17:0)

C41H77O11P (776.5203)

PG(a-17:0/18:1(9Z)-O(12,13))

C41H77O11P (776.5203)

PG(18:1(9Z)-O(12,13)/a-17:0)

C41H77O11P (776.5203)

PG(i-17:0/18:1(12Z)-O(9S,10R))

C41H77O11P (776.5203)

PG(18:1(12Z)-O(9S,10R)/i-17:0)

C41H77O11P (776.5203)

PG(i-17:0/18:1(9Z)-O(12,13))

C41H77O11P (776.5203)

PG(18:1(9Z)-O(12,13)/i-17:0)

C41H77O11P (776.5203)

PA(21:0/18:1(12Z)-2OH(9,10))

C42H81O10P (776.5567)

PA(18:1(12Z)-2OH(9,10)/21:0)

C42H81O10P (776.5567)

PA(a-21:0/18:1(12Z)-2OH(9,10))

C42H81O10P (776.5567)

PA(18:1(12Z)-2OH(9,10)/a-21:0)

C42H81O10P (776.5567)

PA(i-21:0/18:1(12Z)-2OH(9,10))

C42H81O10P (776.5567)

PA(18:1(12Z)-2OH(9,10)/i-21:0)

C42H81O10P (776.5567)

SM(d17:1/22:6(5Z,7Z,10Z,13Z,16Z,19Z)-OH(4))

C44H77N2O7P (776.5468)

SM(d17:1/22:6(4Z,8Z,10Z,13Z,16Z,19Z)-OH(7))

C44H77N2O7P (776.5468)

SM(d17:1/22:6(4Z,7Z,10Z,12E,16Z,19Z)-OH(14))

C44H77N2O7P (776.5468)

SM(d17:1/22:6(4Z,7Z,10Z,13E,15E,19Z)-OH(17))

C44H77N2O7P (776.5468)

SM(d17:1/22:5(4Z,7Z,10Z,13Z,19Z)-O(16,17))

C44H77N2O7P (776.5468)

SM(d16:2(4E,8Z)/22:6(5Z,8E,10Z,13Z,15E,19Z)-2OH(7S, 17S))

C43H73N2O8P (776.5104)

SM(d16:2(4E,8Z)/22:6(4Z,7Z,11E,13Z,15E,19Z)-2OH(10S,17))

C43H73N2O8P (776.5104)

(1R,4E,5R,6R,6R,7S,8S,10S,11S,12R,14S,15R,16S,18E,20E,22S,25R,27S,29S)-22-Ethyl-7,11,14,15-tetrahydroxy-6-(2-hydroxypropyl)-5,6,8,10,12,14,16,29-octamethylspiro[2,26-dioxabicyclo[23.3.1]nonacosa-4,18,20-triene-27,2-oxane]-3,9,13-trione

C44H72O11 (776.5074)

2-[[(2R)-2-[(4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-hexaenoyl]oxy-3-[(Z)-tetradec-9-enoyl]oxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

C44H75NO8P+ (776.523)

2-[hydroxy-[(2R)-2-[(6Z,9Z,12Z,15Z)-octadeca-6,9,12,15-tetraenoyl]oxy-3-[(6Z,9Z,12Z)-octadeca-6,9,12-trienoyl]oxypropoxy]phosphoryl]oxyethyl-trimethylazanium

C44H75NO8P+ (776.523)

2-[hydroxy-[(2R)-2-[(6Z,9Z,12Z,15Z)-octadeca-6,9,12,15-tetraenoyl]oxy-3-[(9Z,12Z,15Z)-octadeca-9,12,15-trienoyl]oxypropoxy]phosphoryl]oxyethyl-trimethylazanium

C44H75NO8P+ (776.523)

2-[hydroxy-[(2R)-3-[(6Z,9Z,12Z,15Z)-octadeca-6,9,12,15-tetraenoyl]oxy-2-[(6Z,9Z,12Z)-octadeca-6,9,12-trienoyl]oxypropoxy]phosphoryl]oxyethyl-trimethylazanium

C44H75NO8P+ (776.523)

2-[hydroxy-[(2R)-3-[(6Z,9Z,12Z,15Z)-octadeca-6,9,12,15-tetraenoyl]oxy-2-[(9Z,12Z,15Z)-octadeca-9,12,15-trienoyl]oxypropoxy]phosphoryl]oxyethyl-trimethylazanium

C44H75NO8P+ (776.523)

2-[[(2R)-3-[(4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-hexaenoyl]oxy-2-[(Z)-tetradec-9-enoyl]oxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

C44H75NO8P+ (776.523)

2-[[(2R)-2-[(Z)-5-[(1S,2R,3R,5S)-3,5-dihydroxy-2-[(E,3R)-3-hydroxyoct-1-enyl]cyclopentyl]pent-3-enoyl]oxy-3-tetradecanoyloxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

C40H75NO11P+ (776.5077)

2-[[(2R)-3-[(Z)-5-[(1S,2R,3R,5S)-3,5-dihydroxy-2-[(E,3R)-3-hydroxyoct-1-enyl]cyclopentyl]pent-3-enoyl]oxy-2-tetradecanoyloxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

C40H75NO11P+ (776.5077)

2-[[(2R)-2-[(Z,9S,10S)-9,10-dihydroxyoctadec-12-enoyl]oxy-3-[(E)-hexadec-1-enoxy]propoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

C42H83NO9P+ (776.5805)

1-hexadecanoyl-2-(9,10-epoxyoctadecanoyl)-sn-glycero-3-phospho-L-serine

C40H75NO11P- (776.5077)

NAGlySer 18:5/24:4

C47H72N2O7 (776.5339)

NAGlySer 26:7/16:2

C47H72N2O7 (776.5339)

NAGlySer 22:6/20:3

C47H72N2O7 (776.5339)

NAGlySer 20:4/22:5

C47H72N2O7 (776.5339)

NAGlySer 20:5/22:4

C47H72N2O7 (776.5339)

NAGlySer 24:6/18:3

C47H72N2O7 (776.5339)

NAGlySer 22:5/20:4

C47H72N2O7 (776.5339)

NAGlySer 26:6/16:3

C47H72N2O7 (776.5339)

Mgdg O-9:0_28:5

C46H80O9 (776.5802)

Mgdg O-28:5_9:0

C46H80O9 (776.5802)

Mgdg O-18:3_19:2

C46H80O9 (776.5802)

Mgdg O-17:0_20:5

C46H80O9 (776.5802)

Mgdg O-13:0_24:5

C46H80O9 (776.5802)

Mgdg O-19:2_18:3

C46H80O9 (776.5802)

Mgdg O-13:1_24:4

C46H80O9 (776.5802)

Mgdg O-21:1_16:4

C46H80O9 (776.5802)

Mgdg O-26:5_11:0

C46H80O9 (776.5802)

Mgdg O-16:3_21:2

C46H80O9 (776.5802)

Mgdg O-16:4_21:1

C46H80O9 (776.5802)

Mgdg O-17:2_20:3

C46H80O9 (776.5802)

Mgdg O-19:0_18:5

C46H80O9 (776.5802)

Mgdg O-21:2_16:3

C46H80O9 (776.5802)

Mgdg O-15:0_22:5

C46H80O9 (776.5802)

Mgdg O-24:4_13:1

C46H80O9 (776.5802)

Mgdg O-18:4_19:1

C46H80O9 (776.5802)

Mgdg O-22:4_15:1

C46H80O9 (776.5802)

Mgdg O-19:1_18:4

C46H80O9 (776.5802)

Mgdg O-15:1_22:4

C46H80O9 (776.5802)

Mgdg O-22:5_15:0

C46H80O9 (776.5802)

Mgdg O-20:5_17:0

C46H80O9 (776.5802)

Mgdg O-24:5_13:0

C46H80O9 (776.5802)

Mgdg O-18:5_19:0

C46H80O9 (776.5802)

Mgdg O-11:0_26:5

C46H80O9 (776.5802)

Mgdg O-20:3_17:2

C46H80O9 (776.5802)

Mgdg O-20:4_17:1

C46H80O9 (776.5802)

Mgdg O-17:1_20:4

C46H80O9 (776.5802)

[1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-[(10Z,13Z,16Z,19Z)-docosa-10,13,16,19-tetraenoxy]propan-2-yl] (4Z,7Z,10Z,13Z)-hexadeca-4,7,10,13-tetraenoate

C44H73O9P (776.4992)

[1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-[(3Z,6Z,9Z,12Z,15Z)-octadeca-3,6,9,12,15-pentaenoxy]propan-2-yl] (11Z,14Z,17Z)-icosa-11,14,17-trienoate

C44H73O9P (776.4992)

[1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-[(7Z,10Z,13Z)-hexadeca-7,10,13-trienoxy]propan-2-yl] (7Z,10Z,13Z,16Z,19Z)-docosa-7,10,13,16,19-pentaenoate

C44H73O9P (776.4992)

[1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-[(7Z,10Z,13Z,16Z,19Z)-docosa-7,10,13,16,19-pentaenoxy]propan-2-yl] (7Z,10Z,13Z)-hexadeca-7,10,13-trienoate

C44H73O9P (776.4992)

[1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-[(6Z,9Z,12Z,15Z)-octadeca-6,9,12,15-tetraenoxy]propan-2-yl] (8Z,11Z,14Z,17Z)-icosa-8,11,14,17-tetraenoate

C44H73O9P (776.4992)

[1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-[(4Z,7Z,10Z,13Z)-hexadeca-4,7,10,13-tetraenoxy]propan-2-yl] (10Z,13Z,16Z,19Z)-docosa-10,13,16,19-tetraenoate

C44H73O9P (776.4992)

[1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-[(9Z,12Z)-hexadeca-9,12-dienoxy]propan-2-yl] (4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-hexaenoate

C44H73O9P (776.4992)

[1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-[(8Z,11Z,14Z,17Z)-icosa-8,11,14,17-tetraenoxy]propan-2-yl] (6Z,9Z,12Z,15Z)-octadeca-6,9,12,15-tetraenoate

C44H73O9P (776.4992)

[1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-[(5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaenoxy]propan-2-yl] (9Z,12Z,15Z)-octadeca-9,12,15-trienoate

C44H73O9P (776.4992)

[1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-[(11Z,14Z,17Z)-icosa-11,14,17-trienoxy]propan-2-yl] (3Z,6Z,9Z,12Z,15Z)-octadeca-3,6,9,12,15-pentaenoate

C44H73O9P (776.4992)

[1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-[(9Z,12Z,15Z)-octadeca-9,12,15-trienoxy]propan-2-yl] (5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaenoate

C44H73O9P (776.4992)

[1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-[(4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-hexaenoxy]propan-2-yl] (9Z,12Z)-hexadeca-9,12-dienoate

C44H73O9P (776.4992)

PEtOH 20:1_20:5

C45H77O8P (776.5356)

PMeOH 19:1_22:5

C45H77O8P (776.5356)

PEtOH 18:2_22:4

C45H77O8P (776.5356)

PEtOH 18:1_22:5

C45H77O8P (776.5356)

PEtOH 20:3_20:3

C45H77O8P (776.5356)

PEtOH 22:2_18:4

C45H77O8P (776.5356)

PMeOH 21:1_20:5

C45H77O8P (776.5356)

PEtOH 18:3_22:3

C45H77O8P (776.5356)

PEtOH 16:2_24:4

C45H77O8P (776.5356)

PMeOH 21:2_20:4

C45H77O8P (776.5356)

PMeOH 17:2_24:4

C45H77O8P (776.5356)

PEtOH 24:2_16:4

C45H77O8P (776.5356)

PEtOH 20:2_20:4

C45H77O8P (776.5356)

PMeOH 19:2_22:4

C45H77O8P (776.5356)

PEtOH 22:1_18:5

C45H77O8P (776.5356)

PEtOH 18:0_22:6

C45H77O8P (776.5356)

PMeOH 19:0_22:6

C45H77O8P (776.5356)

2,3-bis[[(5Z,7Z,9Z,11Z,13Z)-hexadeca-5,7,9,11,13-pentaenoyl]oxy]propyl (5Z,7Z,9Z,11Z,13Z)-hexadeca-5,7,9,11,13-pentaenoate

C51H68O6 (776.5016)

6-[2-heptadecanoyloxy-3-[(3Z,6Z,9Z,12Z,15Z)-octadeca-3,6,9,12,15-pentaenoyl]oxypropoxy]-3,4,5-trihydroxyoxane-2-carboxylic acid

C44H72O11 (776.5074)

6-[3-[(7Z,10Z,13Z)-hexadeca-7,10,13-trienoyl]oxy-2-[(9Z,12Z)-nonadeca-9,12-dienoyl]oxypropoxy]-3,4,5-trihydroxyoxane-2-carboxylic acid

C44H72O11 (776.5074)

3,4,5-trihydroxy-6-[3-[(5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaenoyl]oxy-2-pentadecanoyloxypropoxy]oxane-2-carboxylic acid

C44H72O11 (776.5074)

[2-[(9Z,12Z,15Z)-octadeca-9,12,15-trienoyl]oxy-3-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypropyl] (9Z,12Z)-octadeca-9,12-dienoate

C45H76O10 (776.5438)

[2-[(4Z,7Z,10Z,13Z)-hexadeca-4,7,10,13-tetraenoyl]oxy-3-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypropyl] (Z)-icos-11-enoate

C45H76O10 (776.5438)

[2-[(6Z,9Z,12Z,15Z)-octadeca-6,9,12,15-tetraenoyl]oxy-3-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypropyl] (Z)-octadec-9-enoate

C45H76O10 (776.5438)

[1-hexadecanoyloxy-3-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypropan-2-yl] (5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaenoate

C45H76O10 (776.5438)

[1-[(9Z,12Z)-hexadeca-9,12-dienoyl]oxy-3-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypropan-2-yl] (11Z,14Z,17Z)-icosa-11,14,17-trienoate

C45H76O10 (776.5438)

6-[3-[(7Z,10Z,13Z,16Z,19Z)-docosa-7,10,13,16,19-pentaenoyl]oxy-2-tridecanoyloxypropoxy]-3,4,5-trihydroxyoxane-2-carboxylic acid

C44H72O11 (776.5074)

6-[3-[(10Z,13Z,16Z,19Z)-docosa-10,13,16,19-tetraenoyl]oxy-2-[(Z)-tridec-9-enoyl]oxypropoxy]-3,4,5-trihydroxyoxane-2-carboxylic acid

C44H72O11 (776.5074)

[2-[(7Z,10Z,13Z)-hexadeca-7,10,13-trienoyl]oxy-3-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypropyl] (11Z,14Z)-icosa-11,14-dienoate

C45H76O10 (776.5438)

6-[2-[(9Z,12Z)-heptadeca-9,12-dienoyl]oxy-3-[(9Z,12Z,15Z)-octadeca-9,12,15-trienoyl]oxypropoxy]-3,4,5-trihydroxyoxane-2-carboxylic acid

C44H72O11 (776.5074)

3,4,5-trihydroxy-6-[3-[(8Z,11Z,14Z,17Z)-icosa-8,11,14,17-tetraenoyl]oxy-2-[(Z)-pentadec-9-enoyl]oxypropoxy]oxane-2-carboxylic acid

C44H72O11 (776.5074)

[2-[(3Z,6Z,9Z,12Z,15Z)-octadeca-3,6,9,12,15-pentaenoyl]oxy-3-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypropyl] octadecanoate

C45H76O10 (776.5438)

[1-[(Z)-hexadec-9-enoyl]oxy-3-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypropan-2-yl] (8Z,11Z,14Z,17Z)-icosa-8,11,14,17-tetraenoate

C45H76O10 (776.5438)

6-[3-[(4Z,7Z,10Z,13Z)-hexadeca-4,7,10,13-tetraenoyl]oxy-2-[(Z)-nonadec-9-enoyl]oxypropoxy]-3,4,5-trihydroxyoxane-2-carboxylic acid

C44H72O11 (776.5074)

6-[2-[(Z)-heptadec-9-enoyl]oxy-3-[(6Z,9Z,12Z,15Z)-octadeca-6,9,12,15-tetraenoyl]oxypropoxy]-3,4,5-trihydroxyoxane-2-carboxylic acid

C44H72O11 (776.5074)

[1-tetradecanoyloxy-3-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypropan-2-yl] (7Z,10Z,13Z,16Z,19Z)-docosa-7,10,13,16,19-pentaenoate

C45H76O10 (776.5438)

[1-[(Z)-tetradec-9-enoyl]oxy-3-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypropan-2-yl] (10Z,13Z,16Z,19Z)-docosa-10,13,16,19-tetraenoate

C45H76O10 (776.5438)

[1-hydroxy-3-[hydroxy-[3-hydroxy-2-[(Z)-tetradec-9-enoyl]oxypropoxy]phosphoryl]oxypropan-2-yl] docosanoate

C42H81O10P (776.5567)

[1-[(2-decanoyloxy-3-hydroxypropoxy)-hydroxyphosphoryl]oxy-3-hydroxypropan-2-yl] (Z)-hexacos-15-enoate

C42H81O10P (776.5567)

[1-hydroxy-3-[hydroxy-(3-hydroxy-2-tetradecanoyloxypropoxy)phosphoryl]oxypropan-2-yl] (Z)-docos-13-enoate

C42H81O10P (776.5567)

[1-[[2-[(Z)-hexadec-9-enoyl]oxy-3-hydroxypropoxy]-hydroxyphosphoryl]oxy-3-hydroxypropan-2-yl] icosanoate

C42H81O10P (776.5567)

[1-hydroxy-3-[hydroxy-[3-hydroxy-2-[(Z)-pentadec-9-enoyl]oxypropoxy]phosphoryl]oxypropan-2-yl] henicosanoate

C42H81O10P (776.5567)

[1-[(2-heptadecanoyloxy-3-hydroxypropoxy)-hydroxyphosphoryl]oxy-3-hydroxypropan-2-yl] (Z)-nonadec-9-enoate

C42H81O10P (776.5567)

[1-[(2-dodecanoyloxy-3-hydroxypropoxy)-hydroxyphosphoryl]oxy-3-hydroxypropan-2-yl] (Z)-tetracos-13-enoate

C42H81O10P (776.5567)

[1-[[2-[(Z)-heptadec-9-enoyl]oxy-3-hydroxypropoxy]-hydroxyphosphoryl]oxy-3-hydroxypropan-2-yl] nonadecanoate

C42H81O10P (776.5567)

[1-hydroxy-3-[hydroxy-(3-hydroxy-2-pentadecanoyloxypropoxy)phosphoryl]oxypropan-2-yl] (Z)-henicos-11-enoate

C42H81O10P (776.5567)

[1-hydroxy-3-[hydroxy-[3-hydroxy-2-[(Z)-octadec-9-enoyl]oxypropoxy]phosphoryl]oxypropan-2-yl] octadecanoate

C42H81O10P (776.5567)

[1-hydroxy-3-[hydroxy-[3-hydroxy-2-[(Z)-tridec-9-enoyl]oxypropoxy]phosphoryl]oxypropan-2-yl] tricosanoate

C42H81O10P (776.5567)

[1-[(2-hexadecanoyloxy-3-hydroxypropoxy)-hydroxyphosphoryl]oxy-3-hydroxypropan-2-yl] (Z)-icos-11-enoate

C42H81O10P (776.5567)

[2-[(4Z,7Z,10Z,13Z)-hexadeca-4,7,10,13-tetraenoyl]oxy-3-phosphonooxypropyl] (15Z,18Z)-hexacosa-15,18-dienoate

C45H77O8P (776.5356)

[1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-heptadecanoyloxypropan-2-yl] (Z)-nonadec-9-enoate

C42H81O10P (776.5567)

[2-[(6Z,9Z,12Z,15Z)-octadeca-6,9,12,15-tetraenoyl]oxy-3-phosphonooxypropyl] (13Z,16Z)-tetracosa-13,16-dienoate

C45H77O8P (776.5356)

[1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-tetradecanoyloxypropan-2-yl] (Z)-docos-13-enoate

C42H81O10P (776.5567)

(1-icosanoyloxy-3-phosphonooxypropan-2-yl) (4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-hexaenoate

C45H77O8P (776.5356)

[1-[(Z)-icos-11-enoyl]oxy-3-phosphonooxypropan-2-yl] (7Z,10Z,13Z,16Z,19Z)-docosa-7,10,13,16,19-pentaenoate

C45H77O8P (776.5356)

[3-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-2-[(Z)-tridec-9-enoyl]oxypropyl] tricosanoate

C42H81O10P (776.5567)

[1-decanoyloxy-3-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxypropan-2-yl] (Z)-hexacos-15-enoate

C42H81O10P (776.5567)

[1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-pentadecanoyloxypropan-2-yl] (Z)-henicos-11-enoate

C42H81O10P (776.5567)

[1-[(9Z,12Z)-octadeca-9,12-dienoyl]oxy-3-phosphonooxypropan-2-yl] (12Z,15Z,18Z,21Z)-tetracosa-12,15,18,21-tetraenoate

C45H77O8P (776.5356)

[3-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-2-[(Z)-tetradec-9-enoyl]oxypropyl] docosanoate

C42H81O10P (776.5567)

[2-[(3Z,6Z,9Z,12Z,15Z)-octadeca-3,6,9,12,15-pentaenoyl]oxy-3-phosphonooxypropyl] (Z)-tetracos-13-enoate

C45H77O8P (776.5356)

[1-[(11Z,14Z,17Z)-icosa-11,14,17-trienoyl]oxy-3-phosphonooxypropan-2-yl] (10Z,13Z,16Z)-docosa-10,13,16-trienoate

C45H77O8P (776.5356)

[2-[(5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaenoyl]oxy-3-phosphonooxypropyl] (Z)-docos-13-enoate

C45H77O8P (776.5356)

[1-[(9Z,12Z)-hexadeca-9,12-dienoyl]oxy-3-phosphonooxypropan-2-yl] (14Z,17Z,20Z,23Z)-hexacosa-14,17,20,23-tetraenoate

C45H77O8P (776.5356)

[2-[(8Z,11Z,14Z,17Z)-icosa-8,11,14,17-tetraenoyl]oxy-3-phosphonooxypropyl] (13Z,16Z)-docosa-13,16-dienoate

C45H77O8P (776.5356)

[1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-dodecanoyloxypropan-2-yl] (Z)-tetracos-13-enoate

C42H81O10P (776.5567)

[3-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-2-[(Z)-pentadec-9-enoyl]oxypropyl] henicosanoate

C42H81O10P (776.5567)

[1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-hexadecanoyloxypropan-2-yl] (Z)-icos-11-enoate

C42H81O10P (776.5567)

[3-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-2-[(Z)-heptadec-9-enoyl]oxypropyl] nonadecanoate

C42H81O10P (776.5567)

[3-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-2-[(Z)-hexadec-9-enoyl]oxypropyl] icosanoate

C42H81O10P (776.5567)

[1-[(11Z,14Z)-icosa-11,14-dienoyl]oxy-3-phosphonooxypropan-2-yl] (10Z,13Z,16Z,19Z)-docosa-10,13,16,19-tetraenoate

C45H77O8P (776.5356)

[(2R)-3-[[(2S)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxy-2-[(E)-octadec-9-enoyl]oxypropyl] octadecanoate

C42H81O10P (776.5567)

[(2R)-2-[(6E,9E,12E,15E)-octadeca-6,9,12,15-tetraenoyl]oxy-3-[(2S,5S,6S)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypropyl] (E)-octadec-13-enoate

C45H76O10 (776.5438)

[(2R)-2-[(9E,12E)-octadeca-9,12-dienoyl]oxy-3-phosphonooxypropyl] (5E,8E,11E,14E)-tetracosa-5,8,11,14-tetraenoate

C45H77O8P (776.5356)

[1-carboxy-3-[2-[(3E,6E,9E)-dodeca-3,6,9-trienoyl]oxy-3-[(5E,8E,11E,14E,17E,20E,23E)-hexacosa-5,8,11,14,17,20,23-heptaenoyl]oxypropoxy]propyl]-trimethylazanium

C48H74NO7+ (776.5465)

2-[hydroxy-[(2R)-3-[(9E,11E,13E,15E)-octadeca-9,11,13,15-tetraenoyl]oxy-2-[(6E,9E,12E)-octadeca-6,9,12-trienoyl]oxypropoxy]phosphoryl]oxyethyl-trimethylazanium

C44H75NO8P+ (776.523)

2-[hydroxy-[(2R)-3-[(6E,9E,12E,15E)-octadeca-6,9,12,15-tetraenoyl]oxy-2-[(9E,12E,15E)-octadeca-9,12,15-trienoyl]oxypropoxy]phosphoryl]oxyethyl-trimethylazanium

C44H75NO8P+ (776.523)

[(2R)-2-[(5E,8E,11E,14E)-icosa-5,8,11,14-tetraenoyl]oxy-3-phosphonooxypropyl] (13E,16E)-docosa-13,16-dienoate

C45H77O8P (776.5356)

[(2R)-2-[(11E,14E)-icosa-11,14-dienoyl]oxy-3-phosphonooxypropyl] (7E,10E,13E,16E)-docosa-7,10,13,16-tetraenoate

C45H77O8P (776.5356)

[2-[(9E,11E,13E)-hexadeca-9,11,13-trienoyl]oxy-3-phosphonooxypropyl] (17E,20E,23E)-hexacosa-17,20,23-trienoate

C45H77O8P (776.5356)

[1-carboxy-3-[3-[(7E,9E,11E,13E,15E,17E,19E)-docosa-7,9,11,13,15,17,19-heptaenoyl]oxy-2-[(9E,11E,13E)-hexadeca-9,11,13-trienoyl]oxypropoxy]propyl]-trimethylazanium

C48H74NO7+ (776.5465)

[(2R)-1-[(9E,12E,15E)-octadeca-9,12,15-trienoyl]oxy-3-[(2S,5S,6S)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypropan-2-yl] (9E,11E)-octadeca-9,11-dienoate

C45H76O10 (776.5438)

[(2R)-3-[[(2S)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxy-2-[(E)-hexadec-7-enoyl]oxypropyl] icosanoate

C42H81O10P (776.5567)

[2-[(7E,9E,11E,13E)-hexadeca-7,9,11,13-tetraenoyl]oxy-3-[(2S,5S,6S)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypropyl] (E)-icos-11-enoate

C45H76O10 (776.5438)

2-[[(2R)-2-[(4E,7E,10E,13E,16E,19E)-docosa-4,7,10,13,16,19-hexaenoyl]oxy-3-[(E)-tetradec-9-enoyl]oxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

C44H75NO8P+ (776.523)

[2-[(9E,11E,13E)-hexadeca-9,11,13-trienoyl]oxy-3-[(2S,5S,6S)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypropyl] (11E,14E)-icosa-11,14-dienoate

C45H76O10 (776.5438)

[(2R)-1-[(9E,12E)-octadeca-9,12-dienoyl]oxy-3-phosphonooxypropan-2-yl] (5E,8E,11E,14E)-tetracosa-5,8,11,14-tetraenoate

C45H77O8P (776.5356)

[(2R)-1-[(9E,11E,13E,15E)-octadeca-9,11,13,15-tetraenoyl]oxy-3-[(2S,5S,6S)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypropan-2-yl] (E)-octadec-11-enoate

C45H76O10 (776.5438)

[2-[(4E,7E)-hexadeca-4,7-dienoyl]oxy-3-phosphonooxypropyl] (14E,17E,20E,23E)-hexacosa-14,17,20,23-tetraenoate

C45H77O8P (776.5356)

[(2R)-2-[(E)-hexadec-9-enoyl]oxy-3-[(2S,5S,6S)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypropyl] (7E,10E,13E,16E)-icosa-7,10,13,16-tetraenoate

C45H76O10 (776.5438)

[1-carboxy-3-[3-[(5E,8E,11E,14E,17E)-icosa-5,8,11,14,17-pentaenoyl]oxy-2-[(7E,9E,11E,13E,15E)-octadeca-7,9,11,13,15-pentaenoyl]oxypropoxy]propyl]-trimethylazanium

C48H74NO7+ (776.5465)

[(2R)-2-[(9E,11E)-octadeca-9,11-dienoyl]oxy-3-phosphonooxypropyl] (5E,8E,11E,14E)-tetracosa-5,8,11,14-tetraenoate

C45H77O8P (776.5356)

[(2R)-3-[[(2S)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxy-2-[(E)-octadec-11-enoyl]oxypropyl] octadecanoate

C42H81O10P (776.5567)

[(2R)-2-[(9E,11E,13E,15E)-octadeca-9,11,13,15-tetraenoyl]oxy-3-[(2S,5S,6S)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypropyl] (E)-octadec-4-enoate

C45H76O10 (776.5438)

[(2R)-2-[(9E,12E,15E)-octadeca-9,12,15-trienoyl]oxy-3-[(2S,5S,6S)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypropyl] (9E,12E)-octadeca-9,12-dienoate

C45H76O10 (776.5438)

[(2R)-2-[(6E,9E,12E,15E)-octadeca-6,9,12,15-tetraenoyl]oxy-3-[(2S,5S,6S)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypropyl] (E)-octadec-7-enoate

C45H76O10 (776.5438)

[(2R)-1-[(5E,8E,11E,14E,17E)-icosa-5,8,11,14,17-pentaenoyl]oxy-3-phosphonooxypropan-2-yl] (E)-docos-13-enoate

C45H77O8P (776.5356)

[(2R)-1-[[(2S)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxy-3-[(E)-octadec-13-enoyl]oxypropan-2-yl] octadecanoate

C42H81O10P (776.5567)

[(2R)-2-[(E)-hexadec-7-enoyl]oxy-3-[(2S,5S,6S)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypropyl] (5E,8E,11E,14E)-icosa-5,8,11,14-tetraenoate

C45H76O10 (776.5438)

[3-[2,3-bis[[(4E,7E,10E,13E,16E)-nonadeca-4,7,10,13,16-pentaenoyl]oxy]propoxy]-1-carboxypropyl]-trimethylazanium

C48H74NO7+ (776.5465)

[(2R)-1-[[(2S)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxy-3-[(E)-hexadec-7-enoyl]oxypropan-2-yl] icosanoate

C42H81O10P (776.5567)

[(2R)-2-[(9E,12E,15E)-octadeca-9,12,15-trienoyl]oxy-3-[(2S,5S,6S)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypropyl] (6E,9E)-octadeca-6,9-dienoate

C45H76O10 (776.5438)

[(2R)-2-icosanoyloxy-3-phosphonooxypropyl] (4E,7E,10E,13E,16E,19E)-docosa-4,7,10,13,16,19-hexaenoate

C45H77O8P (776.5356)

[1-carboxy-3-[3-[(4E,7E,10E,13E,16E,19E)-docosa-4,7,10,13,16,19-hexaenoyl]oxy-2-[(7E,9E,11E,13E)-hexadeca-7,9,11,13-tetraenoyl]oxypropoxy]propyl]-trimethylazanium

C48H74NO7+ (776.5465)

[(2R)-1-octadec-17-enoyloxy-3-[(2S,5S,6S)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypropan-2-yl] (6E,9E,12E,15E)-octadeca-6,9,12,15-tetraenoate

C45H76O10 (776.5438)

[(2R)-2-[(E)-icos-11-enoyl]oxy-3-phosphonooxypropyl] (4E,7E,10E,13E,16E)-docosa-4,7,10,13,16-pentaenoate

C45H77O8P (776.5356)

[(2R)-1-[[(2S)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxy-3-[(E)-octadec-6-enoyl]oxypropan-2-yl] octadecanoate

C42H81O10P (776.5567)

[(2S)-1-tetradecanoyloxy-3-[(2R,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypropan-2-yl] (4E,7E,10E,13E,16E)-docosa-4,7,10,13,16-pentaenoate

C45H76O10 (776.5438)

[(2R)-2-[(6E,9E,12E,15E)-octadeca-6,9,12,15-tetraenoyl]oxy-3-[(2S,5S,6S)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypropyl] (E)-octadec-9-enoate

C45H76O10 (776.5438)

[(2S)-1-hexadecanoyloxy-3-[(2R,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypropan-2-yl] (5E,8E,11E,14E,17E)-icosa-5,8,11,14,17-pentaenoate

C45H76O10 (776.5438)

[(2R)-2-[(E)-tetradec-9-enoyl]oxy-3-[(2S,5S,6S)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypropyl] (7E,10E,13E,16E)-docosa-7,10,13,16-tetraenoate

C45H76O10 (776.5438)

[(2R)-2-[(2E,4E)-octadeca-2,4-dienoyl]oxy-3-phosphonooxypropyl] (5E,8E,11E,14E)-tetracosa-5,8,11,14-tetraenoate

C45H77O8P (776.5356)

[(2R)-1-[(6E,9E,12E,15E)-octadeca-6,9,12,15-tetraenoyl]oxy-3-[(2S,5S,6S)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypropan-2-yl] (E)-octadec-6-enoate

C45H76O10 (776.5438)

[(2R)-2-[(E)-icos-11-enoyl]oxy-3-phosphonooxypropyl] (7E,10E,13E,16E,19E)-docosa-7,10,13,16,19-pentaenoate

C45H77O8P (776.5356)

2-[[2-[(5E,7E,9E,11E,13E)-hexadeca-5,7,9,11,13-pentaenoyl]oxy-3-[(11E,14E)-icosa-11,14-dienoyl]oxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

C44H75NO8P+ (776.523)

[(2R)-1-[[(2S)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxy-3-[(E)-heptadec-9-enoyl]oxypropan-2-yl] nonadecanoate

C42H81O10P (776.5567)

[(2S)-3-[[(2R)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxy-2-tetradecanoyloxypropyl] (E)-docos-13-enoate

C42H81O10P (776.5567)

[(2R)-1-[[(2S)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxy-3-[(E)-octadec-11-enoyl]oxypropan-2-yl] octadecanoate

C42H81O10P (776.5567)

[2-[(7E,9E,11E,13E)-hexadeca-7,9,11,13-tetraenoyl]oxy-3-phosphonooxypropyl] (11E,14E)-hexacosa-11,14-dienoate

C45H77O8P (776.5356)

[(2R)-2-[(6E,9E,12E,15E)-octadeca-6,9,12,15-tetraenoyl]oxy-3-[(2S,5S,6S)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypropyl] (E)-octadec-11-enoate

C45H76O10 (776.5438)

[(2R)-2-[(E)-hexadec-7-enoyl]oxy-3-[(2S,5S,6S)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypropyl] (7E,10E,13E,16E)-icosa-7,10,13,16-tetraenoate

C45H76O10 (776.5438)

[(2R)-2-[(9E,11E,13E,15E)-octadeca-9,11,13,15-tetraenoyl]oxy-3-[(2S,5S,6S)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypropyl] (E)-octadec-11-enoate

C45H76O10 (776.5438)

[(2S)-1-[(E)-hexadec-7-enoyl]oxy-3-[(2R,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypropan-2-yl] (5E,8E,11E,14E)-icosa-5,8,11,14-tetraenoate

C45H76O10 (776.5438)

[(2R)-1-[(6E,9E,12E)-octadeca-6,9,12-trienoyl]oxy-3-[(2S,5S,6S)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypropan-2-yl] (9E,12E)-octadeca-9,12-dienoate

C45H76O10 (776.5438)

[(2R)-2-[(6E,9E)-octadeca-6,9-dienoyl]oxy-3-phosphonooxypropyl] (5E,8E,11E,14E)-tetracosa-5,8,11,14-tetraenoate

C45H77O8P (776.5356)

[(2R)-1-[[(2S)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxy-3-tetradecanoyloxypropan-2-yl] (E)-docos-13-enoate

C42H81O10P (776.5567)

[1-carboxy-3-[3-[(7E,9E,11E,13E,15E,17E)-icosa-7,9,11,13,15,17-hexaenoyl]oxy-2-[(9E,11E,13E,15E)-octadeca-9,11,13,15-tetraenoyl]oxypropoxy]propyl]-trimethylazanium

C48H74NO7+ (776.5465)

[(2R)-1-[(9E,12E,15E)-octadeca-9,12,15-trienoyl]oxy-3-[(2S,5S,6S)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypropan-2-yl] (6E,9E)-octadeca-6,9-dienoate

C45H76O10 (776.5438)

[(2R)-2-[(6E,9E,12E)-octadeca-6,9,12-trienoyl]oxy-3-[(2S,5S,6S)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypropyl] (6E,9E)-octadeca-6,9-dienoate

C45H76O10 (776.5438)

[(2R)-1-icosanoyloxy-3-phosphonooxypropan-2-yl] (4E,7E,10E,13E,16E,19E)-docosa-4,7,10,13,16,19-hexaenoate

C45H77O8P (776.5356)

2-[hydroxy-[(2R)-2-[(6E,9E,12E,15E)-octadeca-6,9,12,15-tetraenoyl]oxy-3-[(6E,9E,12E)-octadeca-6,9,12-trienoyl]oxypropoxy]phosphoryl]oxyethyl-trimethylazanium

C44H75NO8P+ (776.523)

[(2R)-1-[(6E,9E,12E,15E)-octadeca-6,9,12,15-tetraenoyl]oxy-3-[(2S,5S,6S)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypropan-2-yl] (E)-octadec-11-enoate

C45H76O10 (776.5438)

[(2R)-2-[(9E,12E,15E)-octadeca-9,12,15-trienoyl]oxy-3-[(2S,5S,6S)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypropyl] (9E,11E)-octadeca-9,11-dienoate

C45H76O10 (776.5438)

[1-carboxy-3-[2-[(7E,9E,11E,13E,15E,17E,19E)-docosa-7,9,11,13,15,17,19-heptaenoyl]oxy-3-[(9E,11E,13E)-hexadeca-9,11,13-trienoyl]oxypropoxy]propyl]-trimethylazanium

C48H74NO7+ (776.5465)

CID 134743757

C45H76O10 (776.5438)

[(2R)-1-[[(2S)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxy-3-[(E)-octadec-4-enoyl]oxypropan-2-yl] octadecanoate

C42H81O10P (776.5567)

[(2R)-1-octadec-17-enoyloxy-3-[(2S,5S,6S)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypropan-2-yl] (9E,11E,13E,15E)-octadeca-9,11,13,15-tetraenoate

C45H76O10 (776.5438)

[(2R)-1-[(E)-icos-11-enoyl]oxy-3-phosphonooxypropan-2-yl] (7E,10E,13E,16E,19E)-docosa-7,10,13,16,19-pentaenoate

C45H77O8P (776.5356)

[(2R)-2-[(E)-hexadec-9-enoyl]oxy-3-[(2S,5S,6S)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypropyl] (5E,8E,11E,14E)-icosa-5,8,11,14-tetraenoate

C45H76O10 (776.5438)

[(2R)-1-[[(2S)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxy-3-[(E)-octadec-7-enoyl]oxypropan-2-yl] octadecanoate

C42H81O10P (776.5567)

[(2R)-1-[(6E,9E)-octadeca-6,9-dienoyl]oxy-3-phosphonooxypropan-2-yl] (5E,8E,11E,14E)-tetracosa-5,8,11,14-tetraenoate

C45H77O8P (776.5356)

2-[hydroxy-[(2R)-2-[(9E,11E,13E,15E)-octadeca-9,11,13,15-tetraenoyl]oxy-3-[(6E,9E,12E)-octadeca-6,9,12-trienoyl]oxypropoxy]phosphoryl]oxyethyl-trimethylazanium

C44H75NO8P+ (776.523)

2-[hydroxy-[(2R)-3-[(6E,9E,12E,15E)-octadeca-6,9,12,15-tetraenoyl]oxy-2-[(6E,9E,12E)-octadeca-6,9,12-trienoyl]oxypropoxy]phosphoryl]oxyethyl-trimethylazanium

C44H75NO8P+ (776.523)

[(2S)-2-decanoyloxy-3-[[(2R)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxypropyl] (E)-hexacos-5-enoate

C42H81O10P (776.5567)

[(2R)-1-[(6E,9E,12E)-octadeca-6,9,12-trienoyl]oxy-3-[(2S,5S,6S)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypropan-2-yl] (9E,11E)-octadeca-9,11-dienoate

C45H76O10 (776.5438)

[1-carboxy-3-[2-[(7E,9E,11E,13E,15E,17E)-icosa-7,9,11,13,15,17-hexaenoyl]oxy-3-[(9E,11E,13E,15E)-octadeca-9,11,13,15-tetraenoyl]oxypropoxy]propyl]-trimethylazanium

C48H74NO7+ (776.5465)

[(2R)-2-octadec-17-enoyloxy-3-[(2S,5S,6S)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypropyl] (6E,9E,12E,15E)-octadeca-6,9,12,15-tetraenoate

C45H76O10 (776.5438)

[(2R)-2-[(E)-icos-13-enoyl]oxy-3-phosphonooxypropyl] (4E,7E,10E,13E,16E)-docosa-4,7,10,13,16-pentaenoate

C45H77O8P (776.5356)

[(2R)-1-[(9E,11E)-octadeca-9,11-dienoyl]oxy-3-phosphonooxypropan-2-yl] (5E,8E,11E,14E)-tetracosa-5,8,11,14-tetraenoate

C45H77O8P (776.5356)

[(2R)-3-[[(2S)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxy-2-[(E)-octadec-13-enoyl]oxypropyl] octadecanoate

C42H81O10P (776.5567)

[(2R)-3-[[(2S)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxy-2-hexadecanoyloxypropyl] (E)-icos-13-enoate

C42H81O10P (776.5567)

[(2R)-2-hexadecanoyloxy-3-[(2S,5S,6S)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypropyl] (5E,8E,11E,14E,17E)-icosa-5,8,11,14,17-pentaenoate

C45H76O10 (776.5438)

[(2R)-1-[(7E,10E,13E,16E)-icosa-7,10,13,16-tetraenoyl]oxy-3-phosphonooxypropan-2-yl] (13E,16E)-docosa-13,16-dienoate

C45H77O8P (776.5356)

[1-carboxy-3-[2-[(4E,7E,10E,13E,16E,19E)-docosa-4,7,10,13,16,19-hexaenoyl]oxy-3-[(7E,9E,11E,13E)-hexadeca-7,9,11,13-tetraenoyl]oxypropoxy]propyl]-trimethylazanium

C48H74NO7+ (776.5465)

[(2R)-2-[(5E,8E)-icosa-5,8-dienoyl]oxy-3-phosphonooxypropyl] (7E,10E,13E,16E)-docosa-7,10,13,16-tetraenoate

C45H77O8P (776.5356)

[(2R)-1-decanoyloxy-3-[[(2S)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxypropan-2-yl] (E)-hexacos-5-enoate

C42H81O10P (776.5567)

[(2R)-3-[[(2S)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxy-2-[(E)-octadec-7-enoyl]oxypropyl] octadecanoate

C42H81O10P (776.5567)

[(2R)-1-[(9E,11E,13E,15E)-octadeca-9,11,13,15-tetraenoyl]oxy-3-[(2S,5S,6S)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypropan-2-yl] (E)-octadec-13-enoate

C45H76O10 (776.5438)

[(2R)-1-[[(2S)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxy-3-[(E)-tetradec-9-enoyl]oxypropan-2-yl] docosanoate

C42H81O10P (776.5567)

CID 134755617

C45H76O10 (776.5438)

[(2R)-2-[(7E,10E,13E,16E)-icosa-7,10,13,16-tetraenoyl]oxy-3-phosphonooxypropyl] (13E,16E)-docosa-13,16-dienoate

C45H77O8P (776.5356)

[2-[(5E,7E,9E,11E,13E)-hexadeca-5,7,9,11,13-pentaenoyl]oxy-3-phosphonooxypropyl] (E)-hexacos-11-enoate

C45H77O8P (776.5356)

2-[hydroxy-[(2R)-2-[(9E,11E,13E,15E)-octadeca-9,11,13,15-tetraenoyl]oxy-3-[(9E,12E,15E)-octadeca-9,12,15-trienoyl]oxypropoxy]phosphoryl]oxyethyl-trimethylazanium

C44H75NO8P+ (776.523)

[(2R)-1-[(9E,11E,13E,15E)-octadeca-9,11,13,15-tetraenoyl]oxy-3-[(2S,5S,6S)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypropan-2-yl] (E)-octadec-9-enoate

C45H76O10 (776.5438)

[(2R)-1-[(2E,4E)-octadeca-2,4-dienoyl]oxy-3-phosphonooxypropan-2-yl] (5E,8E,11E,14E)-tetracosa-5,8,11,14-tetraenoate

C45H77O8P (776.5356)

[(2R)-2-octadec-17-enoyloxy-3-[(2S,5S,6S)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypropyl] (9E,11E,13E,15E)-octadeca-9,11,13,15-tetraenoate

C45H76O10 (776.5438)

[(2R)-1-[(6E,9E,12E,15E)-octadeca-6,9,12,15-tetraenoyl]oxy-3-[(2S,5S,6S)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypropan-2-yl] (E)-octadec-9-enoate

C45H76O10 (776.5438)

[(2S)-3-[[(2R)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxy-2-dodecanoyloxypropyl] (E)-tetracos-15-enoate

C42H81O10P (776.5567)

[(2R)-1-[(9E,12E,15E)-octadeca-9,12,15-trienoyl]oxy-3-[(2S,5S,6S)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypropan-2-yl] (2E,4E)-octadeca-2,4-dienoate

C45H76O10 (776.5438)

[(2S)-3-[[(2R)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxy-2-[(E)-tetradec-9-enoyl]oxypropyl] docosanoate

C42H81O10P (776.5567)

[(2R)-3-[[(2S)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxy-2-hexadecanoyloxypropyl] (E)-icos-11-enoate

C42H81O10P (776.5567)

[(2R)-1-[(E)-icos-13-enoyl]oxy-3-phosphonooxypropan-2-yl] (7E,10E,13E,16E,19E)-docosa-7,10,13,16,19-pentaenoate

C45H77O8P (776.5356)

[(2R)-1-[(9E,11E,13E,15E)-octadeca-9,11,13,15-tetraenoyl]oxy-3-[(2S,5S,6S)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypropan-2-yl] (E)-octadec-7-enoate

C45H76O10 (776.5438)

[(2S)-1-[(E)-hexadec-9-enoyl]oxy-3-[(2R,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypropan-2-yl] (5E,8E,11E,14E)-icosa-5,8,11,14-tetraenoate

C45H76O10 (776.5438)

[(2R)-2-[(5E,8E,11E,14E,17E)-icosa-5,8,11,14,17-pentaenoyl]oxy-3-phosphonooxypropyl] (E)-docos-13-enoate

C45H77O8P (776.5356)

2-[hydroxy-[(2R)-3-[(9E,11E,13E,15E)-octadeca-9,11,13,15-tetraenoyl]oxy-2-[(9E,12E,15E)-octadeca-9,12,15-trienoyl]oxypropoxy]phosphoryl]oxyethyl-trimethylazanium

C44H75NO8P+ (776.523)

CID 134760804

C45H76O10 (776.5438)

[(2R)-1-[(E)-icos-13-enoyl]oxy-3-phosphonooxypropan-2-yl] (4E,7E,10E,13E,16E)-docosa-4,7,10,13,16-pentaenoate

C45H77O8P (776.5356)

[1-carboxy-3-[3-[(7E,10E,13E,16E,19E)-docosa-7,10,13,16,19-pentaenoyl]oxy-2-[(5E,7E,9E,11E,13E)-hexadeca-5,7,9,11,13-pentaenoyl]oxypropoxy]propyl]-trimethylazanium

C48H74NO7+ (776.5465)

[(2R)-1-[[(2S)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxy-3-hexadecanoyloxypropan-2-yl] (E)-icos-13-enoate

C42H81O10P (776.5567)

[(2R)-2-[(9E,11E,13E,15E)-octadeca-9,11,13,15-tetraenoyl]oxy-3-[(2S,5S,6S)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypropyl] (E)-octadec-7-enoate

C45H76O10 (776.5438)

[(2R)-2-[(9E,11E,13E,15E)-octadeca-9,11,13,15-tetraenoyl]oxy-3-[(2S,5S,6S)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypropyl] (E)-octadec-13-enoate

C45H76O10 (776.5438)

2-[[2-[(9E,11E,13E)-hexadeca-9,11,13-trienoyl]oxy-3-[(5E,8E,11E,14E)-icosa-5,8,11,14-tetraenoyl]oxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

C44H75NO8P+ (776.523)

[(2R)-1-[(5E,8E)-icosa-5,8-dienoyl]oxy-3-phosphonooxypropan-2-yl] (7E,10E,13E,16E)-docosa-7,10,13,16-tetraenoate

C45H77O8P (776.5356)

[(2R)-2-[(E)-icos-13-enoyl]oxy-3-phosphonooxypropyl] (7E,10E,13E,16E,19E)-docosa-7,10,13,16,19-pentaenoate

C45H77O8P (776.5356)

[1-carboxy-3-[3-[(3E,6E,9E)-dodeca-3,6,9-trienoyl]oxy-2-[(5E,8E,11E,14E,17E,20E,23E)-hexacosa-5,8,11,14,17,20,23-heptaenoyl]oxypropoxy]propyl]-trimethylazanium

C48H74NO7+ (776.5465)

[(2S)-1-[(E)-hexadec-7-enoyl]oxy-3-[(2R,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypropan-2-yl] (7E,10E,13E,16E)-icosa-7,10,13,16-tetraenoate

C45H76O10 (776.5438)

[(2R)-1-[[(2S)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxy-3-[(E)-pentadec-9-enoyl]oxypropan-2-yl] henicosanoate

C42H81O10P (776.5567)

[(2R)-2-[(9E,12E,15E)-octadeca-9,12,15-trienoyl]oxy-3-[(2S,5S,6S)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypropyl] (2E,4E)-octadeca-2,4-dienoate

C45H76O10 (776.5438)

[(2R)-2-tetradecanoyloxy-3-[(2S,5S,6S)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypropyl] (7E,10E,13E,16E,19E)-docosa-7,10,13,16,19-pentaenoate

C45H76O10 (776.5438)

[(2R)-1-[(11E,14E)-icosa-11,14-dienoyl]oxy-3-phosphonooxypropan-2-yl] (7E,10E,13E,16E)-docosa-7,10,13,16-tetraenoate

C45H77O8P (776.5356)

[(2S)-1-[(E)-hexadec-9-enoyl]oxy-3-[(2R,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypropan-2-yl] (7E,10E,13E,16E)-icosa-7,10,13,16-tetraenoate

C45H76O10 (776.5438)

[(2R)-2-[(6E,9E,12E)-octadeca-6,9,12-trienoyl]oxy-3-[(2S,5S,6S)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypropyl] (9E,12E)-octadeca-9,12-dienoate

C45H76O10 (776.5438)

[(2R)-1-[(9E,11E,13E,15E)-octadeca-9,11,13,15-tetraenoyl]oxy-3-[(2S,5S,6S)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypropan-2-yl] (E)-octadec-6-enoate

C45H76O10 (776.5438)

[(2R)-1-[[(2S)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxy-3-[(E)-hexadec-9-enoyl]oxypropan-2-yl] icosanoate

C42H81O10P (776.5567)

[2-[(5E,7E,9E,11E,13E)-hexadeca-5,7,9,11,13-pentaenoyl]oxy-3-[(2S,5S,6S)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypropyl] icosanoate

C45H76O10 (776.5438)

2-[[2-[(4E,7E)-hexadeca-4,7-dienoyl]oxy-3-[(5E,8E,11E,14E,17E)-icosa-5,8,11,14,17-pentaenoyl]oxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

C44H75NO8P+ (776.523)

[(2R)-3-[[(2S)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxy-2-octadec-17-enoyloxypropyl] octadecanoate

C42H81O10P (776.5567)

[(2R)-2-[(6E,9E,12E,15E)-octadeca-6,9,12,15-tetraenoyl]oxy-3-[(2S,5S,6S)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypropyl] (E)-octadec-4-enoate

C45H76O10 (776.5438)

[(2R)-1-[(9E,11E,13E,15E)-octadeca-9,11,13,15-tetraenoyl]oxy-3-[(2S,5S,6S)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypropan-2-yl] (E)-octadec-4-enoate

C45H76O10 (776.5438)

[(2R)-1-[[(2S)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxy-3-[(E)-octadec-9-enoyl]oxypropan-2-yl] octadecanoate

C42H81O10P (776.5567)

[(2R)-2-[(6E,9E,12E,15E)-octadeca-6,9,12,15-tetraenoyl]oxy-3-[(2S,5S,6S)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypropyl] (E)-octadec-6-enoate

C45H76O10 (776.5438)

[(2R)-1-[[(2S)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxy-3-octadec-17-enoyloxypropan-2-yl] octadecanoate

C42H81O10P (776.5567)

[(2R)-1-[(6E,9E,12E,15E)-octadeca-6,9,12,15-tetraenoyl]oxy-3-[(2S,5S,6S)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypropan-2-yl] (E)-octadec-7-enoate

C45H76O10 (776.5438)

[(2S)-3-[[(2R)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxy-2-[(E)-pentadec-9-enoyl]oxypropyl] henicosanoate

C42H81O10P (776.5567)

[(2R)-3-[[(2S)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxy-2-[(E)-octadec-4-enoyl]oxypropyl] octadecanoate

C42H81O10P (776.5567)

[(2R)-2-[(6E,9E,12E)-octadeca-6,9,12-trienoyl]oxy-3-[(2S,5S,6S)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypropyl] (9E,11E)-octadeca-9,11-dienoate

C45H76O10 (776.5438)

[(2R)-1-[(5E,8E,11E,14E)-icosa-5,8,11,14-tetraenoyl]oxy-3-phosphonooxypropan-2-yl] (13E,16E)-docosa-13,16-dienoate

C45H77O8P (776.5356)

[(2R)-3-[[(2S)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxy-2-[(E)-octadec-6-enoyl]oxypropyl] octadecanoate

C42H81O10P (776.5567)

2-[[2-[(7E,9E,11E,13E)-hexadeca-7,9,11,13-tetraenoyl]oxy-3-[(5E,8E,11E)-icosa-5,8,11-trienoyl]oxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

C44H75NO8P+ (776.523)

[(2R)-1-[(E)-icos-11-enoyl]oxy-3-phosphonooxypropan-2-yl] (4E,7E,10E,13E,16E)-docosa-4,7,10,13,16-pentaenoate

C45H77O8P (776.5356)

[1-carboxy-3-[2-[(5E,8E,11E,14E,17E)-icosa-5,8,11,14,17-pentaenoyl]oxy-3-[(7E,9E,11E,13E,15E)-octadeca-7,9,11,13,15-pentaenoyl]oxypropoxy]propyl]-trimethylazanium

C48H74NO7+ (776.5465)

[(2R)-1-[(6E,9E,12E,15E)-octadeca-6,9,12,15-tetraenoyl]oxy-3-[(2S,5S,6S)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypropan-2-yl] (E)-octadec-13-enoate

C45H76O10 (776.5438)

2,3-bis[[(5E,7E,9E,11E,13E)-hexadeca-5,7,9,11,13-pentaenoyl]oxy]propyl (5E,7E,9E,11E,13E)-hexadeca-5,7,9,11,13-pentaenoate

C51H68O6 (776.5016)

[2-[(4E,7E)-hexadeca-4,7-dienoyl]oxy-3-[(2S,5S,6S)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypropyl] (5E,8E,11E)-icosa-5,8,11-trienoate

C45H76O10 (776.5438)

[(2R)-1-[[(2S)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxy-3-hexadecanoyloxypropan-2-yl] (E)-icos-11-enoate

C42H81O10P (776.5567)

[(2S)-1-tetradecanoyloxy-3-[(2R,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypropan-2-yl] (7E,10E,13E,16E,19E)-docosa-7,10,13,16,19-pentaenoate

C45H76O10 (776.5438)

[(2R)-2-tetradecanoyloxy-3-[(2S,5S,6S)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypropyl] (4E,7E,10E,13E,16E)-docosa-4,7,10,13,16-pentaenoate

C45H76O10 (776.5438)

[(2R)-3-[[(2S)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxy-2-[(E)-heptadec-9-enoyl]oxypropyl] nonadecanoate

C42H81O10P (776.5567)

2-[[(2S)-3-[(4E,7E,10E,13E,16E,19E)-docosa-4,7,10,13,16,19-hexaenoyl]oxy-2-[(E)-tetradec-9-enoyl]oxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

C44H75NO8P+ (776.523)

[(2R)-3-[[(2S)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxy-2-[(E)-hexadec-9-enoyl]oxypropyl] icosanoate

C42H81O10P (776.5567)

[1-carboxy-3-[2-[(7E,10E,13E,16E,19E)-docosa-7,10,13,16,19-pentaenoyl]oxy-3-[(5E,7E,9E,11E,13E)-hexadeca-5,7,9,11,13-pentaenoyl]oxypropoxy]propyl]-trimethylazanium

C48H74NO7+ (776.5465)

[(2R)-2-[(6E,9E,12E)-octadeca-6,9,12-trienoyl]oxy-3-[(2S,5S,6S)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypropyl] (2E,4E)-octadeca-2,4-dienoate

C45H76O10 (776.5438)

[(2R)-1-[(6E,9E,12E)-octadeca-6,9,12-trienoyl]oxy-3-[(2S,5S,6S)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypropan-2-yl] (2E,4E)-octadeca-2,4-dienoate

C45H76O10 (776.5438)

2-[hydroxy-[(2R)-2-[(6E,9E,12E,15E)-octadeca-6,9,12,15-tetraenoyl]oxy-3-[(9E,12E,15E)-octadeca-9,12,15-trienoyl]oxypropoxy]phosphoryl]oxyethyl-trimethylazanium

C44H75NO8P+ (776.523)

[(2R)-1-[(9E,12E,15E)-octadeca-9,12,15-trienoyl]oxy-3-[(2S,5S,6S)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypropan-2-yl] (9E,12E)-octadeca-9,12-dienoate

C45H76O10 (776.5438)

[(2S)-1-[(E)-tetradec-9-enoyl]oxy-3-[(2R,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypropan-2-yl] (7E,10E,13E,16E)-docosa-7,10,13,16-tetraenoate

C45H76O10 (776.5438)

[(2R)-2-[(9E,11E,13E,15E)-octadeca-9,11,13,15-tetraenoyl]oxy-3-[(2S,5S,6S)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypropyl] (E)-octadec-9-enoate

C45H76O10 (776.5438)

CID 134784020

C45H76O10 (776.5438)

[(2R)-2-[(9E,11E,13E,15E)-octadeca-9,11,13,15-tetraenoyl]oxy-3-[(2S,5S,6S)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypropyl] (E)-octadec-6-enoate

C45H76O10 (776.5438)

[(2R)-1-[[(2S)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxy-3-dodecanoyloxypropan-2-yl] (E)-tetracos-15-enoate

C42H81O10P (776.5567)

[(2R)-1-[(6E,9E,12E)-octadeca-6,9,12-trienoyl]oxy-3-[(2S,5S,6S)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypropan-2-yl] (6E,9E)-octadeca-6,9-dienoate

C45H76O10 (776.5438)

[(2R)-1-[(6E,9E,12E,15E)-octadeca-6,9,12,15-tetraenoyl]oxy-3-[(2S,5S,6S)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypropan-2-yl] (E)-octadec-4-enoate

C45H76O10 (776.5438)

2-[hydroxy-[3-[(9Z,12Z)-octadeca-9,12-dienoyl]oxy-2-[(3Z,6Z,9Z,12Z,15Z)-octadeca-3,6,9,12,15-pentaenoyl]oxypropoxy]phosphoryl]oxyethyl-trimethylazanium

C44H75NO8P+ (776.523)

2-[[2-[(4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-hexaenoyl]oxy-3-[(Z)-tetradec-9-enoyl]oxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

C44H75NO8P+ (776.523)

[1-carboxy-3-[2-[(5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaenoyl]oxy-3-[(3Z,6Z,9Z,12Z,15Z)-octadeca-3,6,9,12,15-pentaenoyl]oxypropoxy]propyl]-trimethylazanium

C48H74NO7+ (776.5465)

2-[[3-[(7Z,10Z,13Z)-hexadeca-7,10,13-trienoyl]oxy-2-[(8Z,11Z,14Z,17Z)-icosa-8,11,14,17-tetraenoyl]oxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

C44H75NO8P+ (776.523)

2-[[3-[(4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-hexaenoxy]-2-[(Z)-pentadec-9-enoyl]oxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

C45H79NO7P+ (776.5594)

2-[hydroxy-[2-[(9Z,12Z)-nonadeca-9,12-dienoyl]oxy-3-[(3Z,6Z,9Z,12Z,15Z)-octadeca-3,6,9,12,15-pentaenoxy]propoxy]phosphoryl]oxyethyl-trimethylazanium

C45H79NO7P+ (776.5594)

2-[[3-[(9Z,12Z)-hexadeca-9,12-dienoyl]oxy-2-[(5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaenoyl]oxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

C44H75NO8P+ (776.523)

2-[[2-[(4Z,7Z,10Z,13Z)-hexadeca-4,7,10,13-tetraenoyl]oxy-3-[(11Z,14Z,17Z)-icosa-11,14,17-trienoyl]oxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

C44H75NO8P+ (776.523)

2-[[2-[(9Z,12Z)-heptadeca-9,12-dienoyl]oxy-3-[(5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaenoxy]propoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

C45H79NO7P+ (776.5594)

[1-carboxy-3-[2-[(4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-hexaenoyl]oxy-3-[(4Z,7Z,10Z,13Z)-hexadeca-4,7,10,13-tetraenoyl]oxypropoxy]propyl]-trimethylazanium

C48H74NO7+ (776.5465)

2-[hydroxy-[2-[(6Z,9Z,12Z,15Z)-octadeca-6,9,12,15-tetraenoyl]oxy-3-[(9Z,12Z,15Z)-octadeca-9,12,15-trienoyl]oxypropoxy]phosphoryl]oxyethyl-trimethylazanium

C44H75NO8P+ (776.523)

2-[hydroxy-[3-nonoxy-2-[(7Z,10Z,13Z,16Z,19Z,22Z,25Z)-octacosa-7,10,13,16,19,22,25-heptaenoyl]oxypropoxy]phosphoryl]oxyethyl-trimethylazanium

C45H79NO7P+ (776.5594)

2-[[3-decanoyloxy-2-[(5Z,8Z,11Z,14Z,17Z,20Z,23Z)-hexacosa-5,8,11,14,17,20,23-heptaenoyl]oxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

C44H75NO8P+ (776.523)

2-[hydroxy-[2-[(7Z,10Z,13Z,16Z,19Z,22Z,25Z)-octacosa-7,10,13,16,19,22,25-heptaenoyl]oxy-3-octanoyloxypropoxy]phosphoryl]oxyethyl-trimethylazanium

C44H75NO8P+ (776.523)

2-[[3-[(9Z,12Z)-heptadeca-9,12-dienoxy]-2-[(5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaenoyl]oxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

C45H79NO7P+ (776.5594)

2-[hydroxy-[3-[(6Z,9Z,12Z,15Z,18Z,21Z)-tetracosa-6,9,12,15,18,21-hexaenoxy]-2-[(Z)-tridec-9-enoyl]oxypropoxy]phosphoryl]oxyethyl-trimethylazanium

C45H79NO7P+ (776.5594)

2-[[3-[(5Z,8Z,11Z,14Z,17Z,20Z,23Z)-hexacosa-5,8,11,14,17,20,23-heptaenoxy]-2-undecanoyloxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

C45H79NO7P+ (776.5594)

2-[[2-[(5Z,8Z,11Z,14Z,17Z,20Z,23Z)-hexacosa-5,8,11,14,17,20,23-heptaenoyl]oxy-3-undecoxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

C45H79NO7P+ (776.5594)

2-[[2-[(4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-hexaenoyl]oxy-3-[(Z)-pentadec-9-enoxy]propoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

C45H79NO7P+ (776.5594)

2-[hydroxy-[3-[(9Z,12Z)-nonadeca-9,12-dienoxy]-2-[(3Z,6Z,9Z,12Z,15Z)-octadeca-3,6,9,12,15-pentaenoyl]oxypropoxy]phosphoryl]oxyethyl-trimethylazanium

C45H79NO7P+ (776.5594)

2-[hydroxy-[2-[(6Z,9Z,12Z,15Z,18Z,21Z)-tetracosa-6,9,12,15,18,21-hexaenoyl]oxy-3-[(Z)-tridec-9-enoxy]propoxy]phosphoryl]oxyethyl-trimethylazanium

C45H79NO7P+ (776.5594)

2-[hydroxy-[2-nonanoyloxy-3-[(7Z,10Z,13Z,16Z,19Z,22Z,25Z)-octacosa-7,10,13,16,19,22,25-heptaenoxy]propoxy]phosphoryl]oxyethyl-trimethylazanium

C45H79NO7P+ (776.5594)

1-(9Z-octadecenoyl)-2-octadecanoyl-glycero-3-phospho-(1-sn-glycerol)

C42H81O10P (776.5567)

1-octadecanoyl-2-(9Z-octadecenoyl)-sn-glycero-3-phospho-(1-sn-glycerol)

C42H81O10P (776.5567)

A 1,2-diacyl-sn-glycero-3-phospho-(1-sn-glycerol) in which the 1- and 2-acyl groups are specified as octadecanoyl (stearoyl) and 9Z-octadecenoyl (oleoyl) respectively.

PG(18:0/18:1(11Z))

C42H81O10P (776.5567)

PG(18:1(11Z)/18:0)

C42H81O10P (776.5567)

phosphatidylglycerol 18:0/18:1

C42H81O10P (776.5567)

A phosphatidylglycerol 36:1 in which the acyl group at position 1 contains 18 carbons and no double bonds while that at position 2 contains 18 carbons and 1 double bond.

phosphatidylglycerol 36:1

C42H81O10P (776.5567)

A phosphatidylglycerol in which the two acyl groups contain 36 carbon atoms and 1 double bond.

PG(18:1(9Z)/18:0)

C42H81O10P (776.5567)

SM(39:7)

C44H77N2O7P (776.5468)

Provides by LipidSearch Vendor. © Copyright 2006-2024 Thermo Fisher Scientific Inc. All rights reserved

SQDG(32:2)

C41H76O11S (776.5108)

Provides by LipidSearch Vendor. © Copyright 2006-2024 Thermo Fisher Scientific Inc. All rights reserved

LBPA(36:1)

C42H81O10P (776.5567)

Provides by LipidSearch Vendor. © Copyright 2006-2024 Thermo Fisher Scientific Inc. All rights reserved

PMe(42:6)

C46H81O7P (776.572)

Provides by LipidSearch Vendor. © Copyright 2006-2024 Thermo Fisher Scientific Inc. All rights reserved

PEt(40:6)

C45H77O8P (776.5356)

Provides by LipidSearch Vendor. © Copyright 2006-2024 Thermo Fisher Scientific Inc. All rights reserved

BisMePA(40:6)

C45H77O8P (776.5356)

Provides by LipidSearch Vendor. © Copyright 2006-2024 Thermo Fisher Scientific Inc. All rights reserved

MGDG 14:0_22:5

C45H76O10 (776.5438)

MGDG 14:1_22:4

C45H76O10 (776.5438)

MGDG 16:0_20:5

C45H76O10 (776.5438)

MGDG 16:1_20:4

C45H76O10 (776.5438)

MGDG 18:1_18:4

C45H76O10 (776.5438)

MGDG 18:2_18:3

C45H76O10 (776.5438)

MGDG O-36:6;O

C45H76O10 (776.5438)

MGDG O-37:5

C46H80O9 (776.5802)

SQMG 32:2

C41H76O11S (776.5108)

DGGA 35:5

C44H72O11 (776.5074)

PA O-18:0/20:3;O4

C41H77O11P (776.5203)

PA O-20:0/22:7;O

C45H77O8P (776.5356)

PA O-38:3;O4

C41H77O11P (776.5203)

PA O-42:7;O

C45H77O8P (776.5356)

PA P-20:0/22:6;O

C45H77O8P (776.5356)

PA P-20:1/22:5;O

C45H77O8P (776.5356)

PA 18:2_24:4

C45H77O8P (776.5356)

PA 20:0_22:6

C45H77O8P (776.5356)

PA 20:1_22:5

C45H77O8P (776.5356)

PA 20:2_22:4

C45H77O8P (776.5356)

PA 20:4_22:2

C45H77O8P (776.5356)

PA 20:5_22:1

C45H77O8P (776.5356)

BMP 36:1

C42H81O10P (776.5567)

HBMP 35:1

C41H77O11P (776.5203)

PG O-16:0/20:2;O

C42H81O10P (776.5567)

PG O-16:2/22:6

C44H73O9P (776.4992)

PG O-18:0/18:2;O

C42H81O10P (776.5567)

PG O-36:2;O

C42H81O10P (776.5567)

PG P-16:1/22:6

C44H73O9P (776.4992)

PG P-16:1/22:6 or PG O-16:2/22:6

C44H73O9P (776.4992)

PG P-18:0/18:1;O

C42H81O10P (776.5567)

PG P-38:7

C44H73O9P (776.4992)

PG P-38:7 or PG O-38:8

C44H73O9P (776.4992)

PG 10:0_26:1

C42H81O10P (776.5567)

PG 12:0_24:1

C42H81O10P (776.5567)

PG 14:0_22:1

C42H81O10P (776.5567)

PG 14:1_22:0

C42H81O10P (776.5567)

PG 15:1_21:0

C42H81O10P (776.5567)

PG 16:0_20:1

C42H81O10P (776.5567)

PG 16:1_20:0

C42H81O10P (776.5567)

PG 17:1_19:0

C42H81O10P (776.5567)

PG 18:0_18:1

C42H81O10P (776.5567)

PG 18:0/18:1

C42H81O10P (776.5567)

PG 18:1/18:0

C42H81O10P (776.5567)

PG 32:0/4:1

C42H81O10P (776.5567)

PEth 39:7;O

C44H73O9P (776.4992)

PEth 40:6

C45H77O8P (776.5356)

PM 40:7;O

C44H73O9P (776.4992)

PM 41:6

C45H77O8P (776.5356)

(8e,10e,14e,16r,17r)-6-hydroxy-4,14,16-trimethyl-17-[(2s,4r,8s,10z,12e,15s,16s,18r,19s,20r)-4,16,18,20-tetrahydroxy-8-methoxy-15,19-dimethyl-22-oxo-1-oxacyclodocosa-10,12-dien-2-yl]octadeca-8,10,14-trienoic acid

C45H76O10 (776.5438)

6-hydroxy-4,14,16-trimethyl-17-(4,16,18,20-tetrahydroxy-8-methoxy-15,19-dimethyl-22-oxo-1-oxacyclodocosa-10,12-dien-2-yl)octadeca-8,10,14-trienoic acid

C45H76O10 (776.5438)

22-ethyl-7,11,14,15-tetrahydroxy-6'-(2-hydroxypropyl)-5',6,8,10,12,14,16,29-octamethyl-2,26-dioxaspiro[bicyclo[23.3.1]nonacosane-27,2'-oxane]-4,18,20-triene-3,9,13-trione

C44H72O11 (776.5074)

1-(octadeca-9,12-dienoyloxy)-3-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}propan-2-yl octadeca-9,12,15-trienoate

C45H76O10 (776.5438)

(2s)-1-[(9z,12z)-octadeca-9,12-dienoyloxy]-3-{[(2r,3r,4s,5r,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}propan-2-yl (9z,12z,15z)-octadeca-9,12,15-trienoate

C45H76O10 (776.5438)

(2r)-2-[(9z,12z)-octadeca-9,12-dienoyloxy]-3-{[(2r,3r,4s,5r,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}propyl (9z,12z,15z)-octadeca-9,12,15-trienoate

C45H76O10 (776.5438)